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ANA Antinuclear Antibodies 
ACR American College of Rheumatology 
AECG American-European Consensus Group 
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BAFF B-cell Activating Factor 
CMV Cytomegalovirus 
CRP C-Reactive Protein 
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EGM Extraglandular manifestations 
EULAR European League Against Rheumatism 
GC Germinal Center 
HepC Hepatitis C 
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HIV Human Immunodeficiency Virus  
jSS Juvenile Sjögren’s Syndrome 
kD kiloDalton 
MALT Mucosa-associated Lymphoid Tissue 
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MRI Magnetic Resonance Imaging 
MSG Minor salivary gland 
NHL Non-Hodgkin’s Lymphoma 
pSS Primary Sjögren’s Syndrome 
SGUS Salivary Gland Ultrasonography 
RA Rheumatoid Arthritis 
US Ultrasonography 
Ro/SSA Robert/Sjögren’s-syndrome-related Antigen A 
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Primary Sjögrens’s syndrome (pSS) is a systemic autoimmune disease, mainly 
affecting the salivary and lacrimal glands. Primary SS can also affect the younger 
population and when it does, the denomination is Juvenile SS (jSS). The salivary 
gland component in SS is commonly evaluated by histopathological detection of 
focal mononuclear cell inflammation in a minor labial salivary gland. Other methods 
are needed when a lip biopsy is inconclusive or cannot be performed. Interest in non-
invasive major salivary gland ultrasonography (SGUS) is increasing for both clinical 
practice and research.  
Aim 
To investigate the use of SGUS in the diagnostic evaluation of pSS and jSS. 
Methods 
In Paper I, we included 97 well-characterized pSS patients. Paper II included 
patients diagnosed with jSS at the age of 18 years or younger, and younger than 25 
years at inclusion. The cohort in Paper III consisted of 32 consecutive SS patients.  
In Paper I-III, we collected clinical data and performed a clinical examination 
including Schirmer’s I-test and sialometry. In Paper I and Paper III, we also included 
new serology/laboratory tests. For all three papers, SGUS of the parotid and 
submandibular glands was performed and evaluated using a simplified scoring system 
(0-3). In Paper I, the SGUS examinations were digitally stored as images and 
evaluated and scored at a later time-point. In Paper II, the SGUS examinations were 
evaluated and scored bedside. In Paper III, the SGUS examinations were evaluated 
and scored both bedside and post-examination. Post-examination evaluation and 
scoring was performed on both images and videos, at two different time-points.  
9 
Results 
In Paper I, the female:male ratio was 91:6 (15.2:1), and the mean age 61.3 years. All 
patients fulfilled the AECG classification criteria for pSS. We found pathological 
SGUS findings (SGUS+) in 51/97 patients (52.6% sensitivity). SGUS+ was 
associated with hyposalivation, reduced tear secretion, and elevated titers of anti-
Ro/SSA and anti-La/SSB. 
In Paper II, the female:male ratio was 58:9 (6.4:1). Mean age at first symptom was 
10.2 years and mean age at diagnosis was 12.1 years. Ocular and oral symptoms were 
noted in 42/67 and 53/66 patients, respectively. The AECG or ACR/EULAR 
classification criteria for pSS were fulfilled by 42/67 patients. SGUS+ was observed 
in 41/67 patients (61.2% sensitivity). The AECG and/or ACR/EULAR criteria was 
fulfilled by 26/41 SGUS+ patients. SGUS+ was associated with hyposalivation and 
elevated titres of anti-Ro/SSA, anti-La/SSB and rheumatoid factor. Salivary gland 
enlargements/parotitis was noted in 37/58 patients and non-significantly associated 
with SGUS+.   
In Paper III, the female:male ratio was 7:1, and the mean age 56 years. The 
ACR/EULAR classification criteria for pSS was fulfilled by 24/42 patients. SGUS+ 
was observed in 14/32 patients (43.8% sensitivity). Results from the first round of 
video and image evaluations were used to calculate interobserver agreement and was 
compared to the bedside evaluations. The second round of evaluations were 
compared to the first round to calculate intraobserver agreements. The inter- and 
intraobserver agreement was overall good to excellent. Image and video evaluation 
compared to bedside evaluation revealed a slightly better agreement for longitudinal 






Pathological SGUS findings correlate with several clinical and laboratory findings for 
both pSS and jSS, adding important information to the diagnostic evaluation. Using a 
simplified scoring system, both inter- and intrarater correlations were excellent for 
experienced examiners, with longitudinal video of the parotid gland proving most 
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8.1 Primary Sjögren’s syndrome 
Sjögren’s syndrome (SS) is a chronic, autoimmune condition, mainly affecting the 
salivary and lacrimal glands. The hallmark complaints are of dry eyes and mouth 
(keratoconjunctivitis sicca and xerostomia), but patients also frequently present 
symptoms of fatigue, and muscle and joint pain (1, 2). Extraglandular involvement 
such as dry skin, interstitial lung disease, autoimmune hepatitis, primary biliary 
cirrhosis and interstitial nephritis, occur in 70-80% of patients with pSS (3-5). 
Furthermore, approximately 7.5% of the patients with primary SS (pSS) also develop 
Non-Hodgkin’s lymphoma, 48-75% being MALT-lymphomas (6-9). 
Focal mononuclear cell inflammation in the minor labial salivary gland biopsy, 
(Figure 1) is an important finding in pSS (10). It is one of the main components of the 
classification criteria addressed later in the thesis. Germinal center (GC)-like 
morphology (GC+) with local and systemic autoantibody production, (11) can be 
observed in 20-25% of lip biopsies attained from pSS patients. Some studies indicate 
that presence of GC-like morphology is associated with increased risk of lymphoma 
(12, 13) whereas one study could not support these findings (14). GC+ patients 
present a distinct salivary proteome (15) closely linked to the biologic state of the 
target organ (16).  
Important immunological markers in pSS include antinuclear antibodies (ANAs) such 
as anti-Ro/SSA and anti-La/SSB, with anti-Ro/SSA as the most specific autoantibody 
for pSS (17). Anti-Ro/SSA is also associated with several other autoimmune diseases 
and may be present in the serum of patients with rheumatoid arthritis, primary biliary 
cholangitis, systemic lupus erythematosus, systemic sclerosis, idiopathic 





with anti-Ro/SSA have an increased risk for having a child with neonatal lupus 
and/or congenital heart block (18, 19). Maternal serum anti-SSA may recognize one 
or two of Ro/SSA cellular proteins with a molecular weight of approximately 52 and 
60 kiloDalton (kD). These antigens are called Ro52 and Ro60. Anti-Ro52 seems to 
have an important role in the development of congenital heart block (20) whereas it 
has been suggested that Ro60 plays an important role in preventing autoimmune 
diseases (21). 
Göransson and colleagues proposed a 0.05% point estimate of pSS in a Norwegian 
study from the western part of Norway (22). In a 2015 meta-analysis, the pooled 
incidence rate for pSS was 6.92 per 100.000 person-years, and the overall prevalence 
rate was 60.82 per 100.000 inhabitants (23) making pSS the second most prevalent 
autoimmune rheumatic disease. Primary SS predominately affects middle-aged 
women with a 9:1 female:male ratio (23). The different estimates of incidence and 
prevalence of SS may partially be a result of different classification criteria for 
patient inclusion over time (Table 1).  
At present, there is no causal treatment for Sjögren’s syndrome. Clinicians often 
concentrate on symptomatic relief, for instance by using artificial tears and saliva, 
and prophylactic measures focusing on good oral hygiene, fluorides, and stimulation 
of saliva (24).  
Management of Sjögren’s syndrome is also influenced by the presence of 
extraglandular manifestations, which may prompt more specific treatment regimes. 
The most commonly used systemic treatment is hydroxychloroquine (HCQ), but a 
randomized controlled trial by Gottenberg et al (25) in 2014 could not document 
improvement of patient reported symptoms of dryness, pain and fatigue after 24 
weeks of treatment with HCQ. For severe pSS related conditions and organ 





cyclophosphamide, azathioprine, cyclosporine, mycophenolate mofetil, or 
chlorambucil may be used (25).  
There has also been two large randomized controlled trials investigating the efficacy 
of rituximab in pSS (26, 27). The follow-up period was for 24 and 48 weeks. Neither 
study met their primary endpoint, but significant reductions in fatigue, dryness VAS 
and an increase in unstimulated salivary flow were observed. The effect of rituximab 
on salivary gland ultrasonography score has also been investigated (28, 29), as will be 
described in more detail in a later section of the thesis.  
 
8.2 Juvenile Sjögren’s syndrome 
Juvenile Sjögren’s syndrome (jSS) is a rare, poorly defined and possibly 
underdiagnosed condition (30, 31). Reports of jSS were noted as early as the 1960s 
(32). Mean age at time of diagnosis is around 10 years (33). The clinical presentation 
is slightly different from pSS, with salivary gland swelling/parotitis seeming more 
common and sicca symptoms less prominent in jSS compared to pSS (33-35). As for 
pSS several organ systems may be affected in jSS, resulting in neurological, 
dermatological, musculoskeletal, vascular, gastrointestinal, respiratory, renal, and 
haematological manifestations (36, 37). Similar to pSS, extraglandular manifestations 
occur in approximately 50.0-84.6% of children with jSS (30, 38).  
 
8.3 Classification criteria for Sjögren’s syndrome 
Since the triad of dry eyes, oral dryness and pain in several joints was first described 





(Table 1), and applied in research papers. Until recently, the most commonly used 
criteria was the American-European Consensus Group (AECG) criteria (10) (Table 
2). The main components in the AECG criteria are the salivary gland component 
assessed by focal mononuclear cell infiltrates in the minor labial salivary glands 
(Figure 1) and detection of autoantibodies in serum (anti-Ro/SSA and/or anti-
La/SSB). Measures of reduced levels of unstimulated salivary secretion (sialometry), 
the detection of morphological and functional abnormalities of the glands by 
scintigraphy or sialography, and the measurement of reduced tear secretion or corneal 
damage are also considered. In addition, subjective symptoms of oral and ocular 
dryness are taken into account (10), representing important symptoms that may 
actually bring about a clinical suspicion of SS.  
In 2012, the American College of Rheumatology (ACR) presented an alternate 
version of the criteria based on the Sjögren’s International Collaborative Clinical 
Alliance (SICCA) cohort. Where the AECG classification criteria (10) consist of both 
subjective symptoms and objective findings, the ACR 2012 criteria (39) favor the 
autoimmune and eye components, in practice excluding the hallmark sicca symptoms. 
To give researchers a single set of consensus measures to classify pSS, a novel set of 
classification criteria for SS were recently presented (17), aiming to replace both the 
provisional 2012 ACR criteria (39) and the revised 2002 AECG classification criteria 
(10). These criteria, termed the ACR/EULAR classification criteria, are based on five 
objective tests/items, resulting in a total score ≥ 4, derived from the sum of the weight 
assigned to each positive test/item (Table 2). 
A Japanese study (40) compared the 1999 revised Japanese Ministry of Health 
criteria for diagnosis of SS (JPN), 2002 American-European Consensus Group 
classification criteria for SS (AECG) and 2012 ACR classification criteria for SS 





Against Rheumatism (EULAR) classification criteria for primary Sjögren's syndrome 
(SS) in Japanese patients. It showed that the ACR/EULAR criteria had significantly 
higher sensitivity, but lower specificity for the diagnosis of pSS, compared to the 
other currently available three sets of criteria. These results were different compared 
to Shibowski et al (17), which showed a higher specificity. It was speculated whether 
this difference was caused by the eight pSS and 11 non-pSS patients in the Japanese 





Table 1. An overview of previous and current classification criteria for SS. 
Classification criteria Published  Reference 
Sjögren’s Disease Research Committee review on research 
reports: Annual report of the Ministry of Health and 
Welfare. Tokyo, Japanese Ministry of Health 
1977 (41) 
Sjögren's syndrome. Proposed criteria for classification 1986 (42) 
Criteria for Sjögren's syndrome in Japan 1986 (43) 
The Copenhagen criteria for Sjögren's syndrome 1986 (44) 
European Community Study Group Criteria (ECSG) 1993 (45) 
Revised Japanese Diagnostic Criteria for Sjögren syndrome 2000 (46) 
American European Consensus Group Criteria (AECG) 2002 (10) 
ACR criteria 2012 (39) 





Figure 1. Minor labial salivary gland tissue section (H&E) from a patient with pSS 
(A). Dense mononuclear focal infiltrates surround the larger ducts and there is 
adjacent normal-appearing acini. Minor salivary gland from a patient with sicca 
symptoms (B). Negative biopsy without focal infiltrates. Atrophy of acinar glands 
and prominent interstitial fibrosis. Scattered lymphocytes and plasma cells mainly 






















































































































































































































































































































































































































































































































































































































































































































































































8.4 Classification criteria for juvenile Sjögren’s syndrome 
Established diagnostic or classification criteria for jSS are not available in current 
literature (48-50). Diagnostic criteria for use on children and adolescents have been 
suggested (Table 3), but have not yet been validated in a large study population (34). 
Neither the AECG criteria (10) nor the ACR/EULAR criteria (51) were validated in a 
juvenile population. In addition, the AECG criteria may not be applicable due to 
diverse clinical symptoms and manifestations in children compared to adults (31, 50). 
For instance recurrent parotitis is often the presenting symptom in jSS and is included 
in the suggested criteria for jSS (Table 3). 
A study by Yokogawa et al (52) in 2016 included 26 jSS patients diagnosed by a 
pediatric rheumatologist. The patients were evaluated with the AECG, ACR and 
Japanese criteria for pSS. They were also evaluated with the suggested jSS criteria 
(34). Interestingly, none of the patients had performed all the necessary test required 
to calculate the sensitivity of the criteria. Only nine (35%) patients met the AECG 
criteria, seven (27%) met the ACR criteria and seven (27%) met the Japanese criteria. 
Clearly, there is a need for distinctive jSS criteria. None of the pSS criteria performed 
better than  the suggested jSS criteria (34). In the paper by Yokogawa et al (52), the 





Table 3. Proposed jSS criteria (34). Table modified from (52) and (34). 
Criteria item 
1 Recurrent parotitis or parotid enlargement 
2 Recurrent conjunctivitis (non-allergic and non-infectious), or 
keratoconjunctivitis sicca 
3 Recurrent vaginitis 
4 Systemic: fever of unknown origin, arthralgias, hypokalemic paralysis, or 
abdominal pain 
5 Ocular dryness (ocular staining or Schirmer’s I-test) 
6 Abnormal sialography 
7 Elevated serum amylase 
8 Leukopenia or elevated ESR 
9 Hyperimmunoglobulinaemia (polyclonal) 
10 Renal tubular acidosis 
11 At least one of: anti-Ro/SSA, anti-La/SSB, high titer ANA (speckled 
pattern), RF 
12 Lymphocytic infiltration of minor labial salivary glands or other organs 
 








8.5 Salivary gland ultrasonography  
Ultrasonography (US) is an imaging method based on sound waves emitted and 
received by Piezo-electric crystals. The parotid and submandibular major salivary 
glands are superficial and well situated for high frequency ultrasonography 
examination (53, 54). High frequency transducers provide high-resolution images, 
with a more detailed image compared to low frequency transducers. Implementation 
of SGUS into clinical practice as a non-invasive imaging technique may aid the 
physician in the diagnostic process, reduce the time-delay associated with other 
diagnostic imaging techniques, confirm a clinical suspicion of disease and in some 
cases even replace the minor labial salivary gland biopsy. Utilization of 
ultrasonography may also prove as a valid method for assessing disease severity and 
progression. The method may prove of special importance in seronegative (ANA-
negative) patients (55).  
Characteristic SGUS findings in pSS consist of inhomogeneity and hypoechogenic 
areas, hyperechogenic reflections and diffuse gland borders (image c and d in Figure 
2). In short, such findings are associated with increased signs and symptoms 
indicative of systemic complications, higher disease activity measured by ESSDAI 
(56), salivary gland swelling, reduced levels of unstimulated whole salivary flow 
(57),  higher MSG focus score (57), and markers of lymphoma development such as 
skin vasculitis, GC-like structures in minor labial salivary gland biopsy and CD4+ T-
lymphocytopenia (58).  
Utilizing SGUS is reported to improve classification criteria for SS (47, 59, 60), but 
one has yet to reach a consensus on standard scoring method for clinical practice. In 
comparison to imaging methods traditionally used for the major salivary glands, 





sialography and scintigraphy (61), and MRI (62). Salivary gland SGUS is also 
convenient for repeated examinations in a clinical setting (63).  
In 2008, Shimzu et al. (64) published a study investigating whether Doppler added to 
SGUS would improve the diagnostic value. Significantly higher vascularity was 
detected in pSS patients compared to controls. Increased vascularity also correlated 
with hisopathological findings in labial MSGs. Adding Doppler, increased the 
sensitivity from 44% to 63%, whereas the specificity decreased from 97% to 90%.  
Other US techniques can also be used to evaluate the salivary gland component of 
pSS. Real-time sonoelastography (RTS) investigates the elasticity of soft tissues, 
based on the principle that tissue compression produces strain (displacement) within 
the tissue that is less pronounced in harder compared to softer tissues (65). The tissue 
elasticity can also be measured using Acoustic Radiation Force Impulse (ARFI) 
ultrasonography (66). When using this technique, the local tissue displacement is 
acquired by a brief acoustic radiation, causing emission and propagation of shear 
waves. The shear wave velocity (SWV) is measured in meters per second and 
increases with tissue stiffness. Studies show that pSS patients have increased stiffness 
in their major salivary glands compared to healthy controls (66, 67).  
As mentioned in an earlier section of this thesis, the effect of rituximab was 
investigated by SGUS (28, 29). The study by Fisher et al (28) in 2018 showed 
improvement in glandular border/definition after 16 and 48 weeks of treatment, but 
could not confirm improvements in homogeneity or hypoechogenic areas as shown 
by Jousse-Joulin et al (29) in 2015. In 2007, Jousse-Joulin et al (68) demonstrated 
altered blood flow in the salivary glands upon lemon stimulation after 12 weeks of 
treatment with rituximab, using Doppler SGUS in pSS patients. The size of the 
submandibular and parotid glands was also reduced. In major salivary gland biopsies, 





observed following treatment with rituximab (69-71), but unfortunately, these studies 
did not include SGUS examination. 
8.6 Applied scoring systems for salivary gland 
ultrasonography 
Throughout the years, several scoring systems for SGUS have been described in the 
literature. One of the first scoring systems was published by Hocevar et al in 2005, 
presenting the diagnostic value of a novel scoring system consisting of five 
parameters (72). The study included 68 patients with confirmed pSS according to the 
AECG classification criteria and 150 patients with suspected pSS. The parameters 
assessed were echogenicity, inhomogeneity, and number of hypoechogenic areas, 
presence of hyperechogenic reflections, and clearness of the salivary gland borders. 
The grades of the five parameters were summarized for all four major salivary glands, 
with a final US score ranging from 0 to 48. Patients with confirmed pSS had a 
significantly higher US score, and with the cut-off at ≥17, the specificity and 
sensitivity was 98.7% and 58.8%, respectively. Simplified scoring systems based on 
Hocevar’s study have since been suggested (58, 73-75). 
To our knowledge, two meta-analyses have been published on SGUS scoring systems 
in the last five years (73, 75). The most recent meta-analysis (73) noted 1301 articles 
describing different scoring systems using the AECG criteria. Out of these, 24 met 
the criteria for quality-assessment and 14 for meta-analysis. Eight of the 24 studies 
that met the quality-assessment criteria used a scoring system of 0-4 and six studies 
used scoring 0-3. Two studies used 0-12, six studies 0-16, five studies 0-48. The 0-4 
scoring system seemed to have the least variations in specificity and diagnostic OR 
(Table 4). Studies using the 0-4 systems had a pre-specified cut-off, whilst the cut-off 
varied in studies using 0-16 and 0-48 systems, resulting in relatively large 





also displayed a shorter operation time and more manageable performance, which is 
of large importance in a clinical setting.   
Using a simplified scoring system, Baldini et al. (57) found that a cut-off of 2 
provided the best ratio of specificity (98%) and sensitivity (66%), in accordance with 
both current and early studies (58, 76). Baldini et al. also found a positive predictive 
value of 97%, and a negative predictive value of 77% for the diagnosis of pSS (57). 
Studies have since indicated that hypoechogenic areas and homogeneity in the parotid 
gland seem to have the highest interobserver reliability (74, 77). Mossel et al (78) 
even found that scoring the parotid and submandibular glands on only one side, was 
sufficient to predict classification of patients in accord to the ACR/EULAR 
classification criteria. In the same paper, Mossel demonstrated that scoring only 
hypoechogenic areas showed close to similar results as scoring all components in the 
previous scoring systems (72); parenchymal echogenicity, 
homogeneity, hypoechogenic areas, hyperechogenic reflections and 
salivary gland posterior border. These findings further support a simplified scoring 







Table 4. The meta-analysis results of three scoring systems (AECG as the diagnostic 







Figure 2. Parenchymal inhomogeneity in the parotid glands demonstrated by 
ultrasonography. Normal parotid gland, grade 0 (a). Parotid gland with mild non-
specific inhomogeneity, grade 1 (b). Parotid gland with evident inhomogeneity, grade 
2 (c). Parotid gland with gross inhomogeneity, grade 3 (d). Figure and text from (57). 
 
8.7 Literature search 






The overall aim of this thesis was to investigate SGUS in pSS and jSS. Moreover, we 
wanted to study the use of SGUS in diagnostic evaluations and the correlation of 
pathological SGUS changes to clinical and laboratory findings. 
 
The specific aims were 
I. To investigate SGUS findings in an adult pSS cohort and to determine 
correlation with symptoms, and clinical and laboratory findings. 
II. To characterize symptoms and clinical findings of jSS, and to explore the 
clinical application of SGUS in patients with jSS. 
III. To determine the gland, projection and format most applicable for 
reproducible image analysis, by comparing inter- and intra-rater 






10. MATERIALS AND METHODS 
10.1 Patient populations 
10.1.1 Paper I 
Patients with pSS were recruited from the Department of Rheumatology, Haukeland 
University Hospital (n=97) and were either previously diagnosed with pSS (n=82) 
and part of a well characterized pSS cohort, or newly diagnosed (n=15) and included 
in the cohort. All patients met the criteria set by the American-European Consensus 
Group (AECG) in 2002 (79). Daniel S. Hammenfors (DH) examined all patients 
alone or together with Malin V. Jonsson (MVJ).  
 
10.1.2 Paper II 
The study design was a cross-sectional multicentre study. Patients were recruited 
from Haukeland University Hospital in Bergen, Norway, Oslo University Hospital, 
Norway, Hospital General Universitario Gregorio Marañón in Madrid, Spain, 
Hospital Universitário Cassiano Antônio Moraes of Federal University of Espírito 
Santo in Vitória, Brazil, Hospital Universitário Clementino Fraga Filho, Federal 
University of Rio de Janeiro in Brazil and Hospital das Clinicas, Faculdade de 
Medicina da Universidade de Sao Paulo (HCFMUSP) in Brazil, University Medical 
Center Groningen, the Netherlands, and Department of Pediatrics, University of 
Florida, Gainesville, Florida.  
Patients had previously received the diagnosis jSS, by a specialist in rheumatology or 
paediatric medicine, at the age of 18 years or younger. At the time of inclusion, all 
patients were younger than 25 years. The local specialist in rheumatology or 





Patients included in Norway (n=11), Spain (n=5) and Brazil (n=40) were examined 
and included by the primary investigators (DH and MVJ), in cooperation with the 
local specialist. Patients recruited from the Netherlands (n=8) and USA (n=3) were 
examined in collaboration with local experts and included retrospectively.  
 
10.1.3 Paper III 
We currently have an ongoing enrolment of patients in the SS cohort denoted S2C, 
including patients diagnosed with SS by a rheumatologist but not necessarily 
fulfilling the 2002 AECG (10) or the 2016 ACR/EULAR classification criteria (17).  
The patients are recruited from the outpatient clinic at the Department of 
Rheumatology, Haukeland University Hospital, Bergen. For this project, data and 
examinations were from the first included patients in S2C (n=32). All patients were 
examined and included by Haris Causevic (HC).  
 
10.2 Salivay gland ultrasonography examination and 
evaluation 
10.2.1 Paper I 
We examined the parotid and submandibular glands by US using a GE LogiqE9 with 
a linear high-frequency transducer (6-15 MHz). The parotid glands were evaluated in 
a longitudinal and cross-sectional plane and the submandibular glands in a 
longitudinal plane (Figure 3). One out of two clinical investigators (DH and MVJ) 
performed the US examination. Representative SGUS images were stored digitally as 
.jpg images and evaluated later on, in a darkened room and on a standard high-quality 





MVJ) who were both blinded for clinical findings such as subjective sicca symptoms, 
sialometry, serum autoantibodies and minor salivary gland inflammatory focus score. 
Glandular homogeneity and presence of hypoechogenic areas were evaluated and 
graded (0-3) using a simplified scoring system, as previously described by Hocevar et 
al 2005 (72) and applied in other studies (58). Grades 0-1 were considered to 
correspond to normal/non-specific changes and grades 2-3 to correspond to 
pathological changes. The number and size of hypoechogenic and/or anechoic areas 
as well as the degree of inhomogeneity presented in both submandibular and parotid 
glands were evaluated and graded by both investigators (DH and MVJ). A final 
overall score was then determined for all glands combined.  
In cases where hypo-/anechoic areas were not detected, the score was set to 0. If 
SGUS showed a few minor focal hypo-/anechoic areas that were considered within 
normal, the score was set to 1. When at least one of the glands was more severely 
affected with multiple focal hypo-/anechoic areas but some homogenous and normal 
appearing salivary gland tissue remained, the score was set to 2 and changes 
considered pathological. In cases of severe generalized affection of at least two of the 
glands with minimal normal appearing glandular tissue remaining, as well as at least 
a grade 2 affection of the remaining gland(s), the score was set to 3.  
 
10.2.2 Paper II 
The SGUS examination of the right and left parotid and submandibular glands was 
performed using linear high-frequency transducers (6-15 MHz). The available local 
hardware was used. Glandular homogeneity and presence of hypoechogenic areas 
were evaluated and graded using a simplified scoring system (0-3) as described for 
Paper I (Figure 2). The SGUS examinations were conducted and scored bedside by 
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local experts in the USA and the Netherlands, and by DH/MVJ in Norway, Spain and 
Brazil.  
10.2.3 Paper III 
Upon inclusion, one clinical investigator (HC) performed SGUS on all patients using 
a GE Logic E9 (GE, USA) with a linear high-frequency transducer (6-15 MHz). Both 
right and left parotid and submandibular glands were examined. All four glands were 
examined in the longitudinal and transversal planes (Figure 3). The projections were 
evaluated bedside by the clinical investigator (HC), and each gland was given a 
composite score (0-3) based on overall impression. Representative videos and static 
images for both the longitudinal and transversal planes of all four glands were 
concurrently stored for documentation and later re-evaluation, in total 16 images 
(eight videos and eight static images) per patient. Using the local institution media 
storage database (Digital Media Archive), videos and images were extracted in dis-
identified format and randomized using a random number generator for evaluation in 
equal consecutive order by three investigators (DH, HC, MVJ), securing a blinded 
evaluation of images and videos. The images and videos were scored using the 
simplified scoring system as described for Papers I&II.  
In a minority of cases where two videos and/or images were available from the same 
gland and projection, and pathological findings for some reason differed, the 
highest/more severe score was noted. All videos and images were evaluated and 
scored by all three investigators at two separate times (round 1 and round 2, 
November 2017 and January 2018). The scores registered in round 1 were used for 
interclass correlation assessment (bedside score compared to image and to video 
scores), and interobserver reliability. The scores registered in round 2 were used for 
calculating intraobserver reliability. 
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Figure 3. Probe placement when examining the parotid gland in the longitudinal (A) 
and transversal (B) planes, and when examining the submandibular gland in the 
longitudinal (C) and transversal (D) planes. Images by Daniel Hammenfors. 
10.3 Sialometry 
Salivary gland functional capacity was evaluated by unstimulated and stimulated 
sialometry of whole saliva, in ml/15 minutes and ml/5 minutes, respectively. The 
clinical investigations were performed in a consecutive setting, starting with the 
unstimulated whole saliva, (UWS) with the patients fasting at least 90 min before 
examination (Figure 4). Stimulated whole saliva (SWS) was obtained by letting 





saliva was collected in pre-weighed containers and the volume of secreted saliva 
determined by weighing, with 1 gram of saliva corresponding to 1 ml. Levels ≤ 1.5 
ml/15 minutes of unstimulated saliva and ≤ 3.5 ml/5 minutes of stimulated saliva 
were considered pathologically reduced. 
 
 
Figure 4. Unstimulated and stimulated sialometry. Necessary equipment constitute 
tract, measuring tube or pre-weighed containers, and a timer. Figure from (81). For 
representative and reproducible results, unstimulated saliva is measured for 15 
minutes, and stimulated saliva for 5 minutes (81, 82). 
 
10.4 Schirmer’s I-test 
Tear secretion was evaluated by the Schirmer’s-I test. Wetting of the strip was 
recorded in mm, with levels of 5 mm or less wetting of the paper strip considered as 







Figure 5. Schirmer’s I-test. The illustration shows an individual with normal tear 
secretion. Image by Daniel Hammenfors. 
 
10.5 Minor labial salivary gland biopsy and evaluation 
Minor labial salivary gland tissue biopsies were not performed as a part of the study, 
and were only obtained if deemed necessary for medical and diagnostic reasons as 
evaluated by the treating rheumatologist/physician. In most cases, the biopsy had 
been performed prior to inclusion.  
The local oral pathologists routinely performed determination of focus score. 
Sections were not re-evaluated for the current research project. Minor salivary gland 
focus score denominates the number of focal mononuclear cell infiltrates with ≥ 50 
cells per 4 mm2 of otherwise normal appearing minor salivary gland tissue (83) 
(Figure 1). In Paper I, data regarding lymphoid neogenesis/germinal center (GC)-like 







10.6 Patient Reported Outcome Measures (PROMS) and 
Disease Severity Scores 
EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) (84) was determined 
in all patients upon inclusion. Severity of sicca symptoms of the mouth and eyes were 
reported by patients on a visual analogue scale (VAS) ranging from 0-10 and the 
level of fatigue on a VAS ranging from 0-100, with a higher number representing 
more severe symptoms.  
EULAR Sjögren’s syndrome disease activity index (ESSDAI) (85) was registered 
upon inclusion for most patients. The haematological and biological domains were 
determined from the most recent blood samples available, if possible obtained the 
same day as inclusion.  
 
10.7 Statistics 
The statistical analyses for all papers were performed using IBM SPSS Statistics 
software (Armonk, NY, IBM Corp), version 19.0 (Paper I-II) and version 24 (Paper 
III).  
The Student’s t-test with Welch’s correction was used to study differences between 
groups (Paper I-III). For categorical data, Chi-square analysis was employed (Paper 
I-III). Spearman (monotonic) and/or Pearson (linear) correlation analysis were used 
to evaluate the relationship between two variables (Paper I-III). The inter- and intra-
observer reliability was assessed by intraclass correlation coefficient (ICC), two-way 
mixed, absolute agreement (Paper III). ICC less than 0.40 were considered poor, 






In general, P values less than 0.05 were considered statistically significant. In Paper 
II, Benjamin-Hochberg adjustment was applied to reduce type 1 errors due to 
multiple comparisons. 
Primarily, DH performed statistical analyses in cooperation with MVJ, Johan G. Brun 
and HC. For Paper II, Jannicke Igland at Department of Global Public Health and 
Primary Care, University of Bergen provided statistical advice. In Paper III, 
statistician and co-author Jörg Assmus was the main statistical advisory.  
 
10.8 Ethical considerations 
The studies (Paper I-III) were approved by the Regional Medical and Health 
Research Ethics Committees (145/96-44.96, 242.06 and 2009/686) and reported to 
the Data Inspectorate (NSD number 9646) in Norway. For patients included abroad 
(Paper II), the inclusion was according to the Regional Medical and Health Research 
Ethical regulations and necessary applications were approved by the regional 
committees in the participating centers/countries. All patients and/or legal guardians 





11. SUMMARY OF RESULTS 
11.1 Diagnostic utility of SGUS in pSS (Paper I) 
In Paper I the female:male ratio was 91:6 (15.2:1), the mean age was 61.3 years.  
Pathological SGUS findings (SGUS+) were determined in 51/97 patients. Oral 
dryness symptoms (VAS) correlated with SGUS score and unstimulated and 
stimulated saliva levels.  
Positive Schirmer’s I-test in one or both eyes was observed in 42/50 (84%) patients 
with pathological US findings, compared to 24/45 (53%) patients with normal/non-
specific US findings, and SGUS scores correlated with tear secretion in both eyes. 
Focus score was available in 81/97 (84%) patients, and correlated with SGUS score. 
Serum autoantibody status was associated with SGUS+ in 44/50 (88%) patients. 
Specifically, serum titers of anti-Ro/SSA were elevated in 41/50 (82%) SGUS+ 
patients compared to 23/46 (50%) SGUS- patients. Anti-La/SSB titers were elevated 
in 29/50 (58%) SGUS+ patients compared to 8/46 (17%) SGUS- patients. 
 
11.2 Clinical characteristics and SGUS in jSS (Paper II) 
In Paper II the female:male ratio was 58:9 (6.4:1). Mean age at first symptom was 
10.2 years, and 12.1 years at diagnosis.Ocular and oral symptoms were noted in 
42/67 (63%) and 53/66 (80%) patients, respectively, with salivary gland 
enlargements/parotitis in 37/58 (64%) patients. AECG or ACR/EULAR classification 
criteria for pSS was fulfilled by 42/67 (63%) patients. Pathological SGUS findings 
(SGUS+) were observed in 41/67 (61%) patients; 26/41 (63%) SGUS+ fulfilled pSS 





3.3 ml/15 minutes in the SGUS+ patients. Among the SGUS+ patients, 36/41 (88%) 
patients were anti-Ro/SSA+ or anti-La/SSB+ compared to 14/26 (54%) SGUS- 
patients. Among the SGUS+ patients 24/39 (62%) patients were RF+, whereas only 
5/25 (20%) SGUS- patients were RF+. Mean ESSDAI was non-significantly higher 
in the SGUS+ compared to the SGUS- patients. 
The majority (54/59, 92%) of the patients with jSS were currently (n=40) or had 
previously (n=14) been treated with HCQ. Most SGUS- patients (22/25, 88%) had 
current treatment with HCQ whilst approximately half of the SGUS+ (18/34, 53%) 
had no current HCQ treatment. Various extraglandular manifestations (EGM) were 
registered for 56/62 (90%) patients and associated with systemic treatment.   
 
11.3 Real-time and post-examination SGUS (Paper III) 
In Paper III the female:male ratio was 28:4 (7:1), the mean age was 56 years. The 
cohort consisted of 32 consecutive patients with a clinical pSS diagnosis. 
ACR/EULAR classification criteria for pSS was fulfilled by 24/32 (75%) patients.  
Bedside SGUS examination revealed pathological findings (score 2-3) in at least two 
glands in 14/32 (44 %) patients. The bedside evaluation was  defined as the gold 
standard for this project, and used for comparison to the evaluation of the digitally 
stored images and videos.  
Comparing interobserver agreement, i.e. evaluation of videos and images to bedside 
evaluation, the ICC between investigators was overall excellent with scores ranging 
from 0.81 to 0.93 in round 1, and from 0.84 to 0.94 in round 2.  
The intraobserver reliability scores had a wider range, from 0.46 to 0.96, depending 





format (video/image). In general, the scores were good, with a slightly higher 
intraobserver reliability ICC mean (for all investigators) for images (0.81) compared 
to video (0.74), and longitudinal (0.80) compared to transversal (0.76) projection. The 
ICC for the parotid and submandibular glands were similar (0.78 and 0.78). 
When comparing round 1 to bedside evaluation, we found that the ICC ranged from 
0.131 to 0.882. The average ICC scores for the three investigators were 0.577, 0.641 
and 0.674. The best agreement between bedside assessment and image/video re-
evaluation was observed for longitudinal video of the right parotid gland, with 
average score 0.772. The poorest agreement between bedside scoring and 
image/video re-evaluation was found for transversal video of the left submandibular 
gland with average score 0.209. The ICC average for longitudinal video was 0.683, 
transversal video 0.510, longitudinal image 0.667 and transversal image 0.662 








Figure 6. Maximum, minimum and average ICC scores for image/video in both 



















12.1 Methodological considerations 
Since first described in 1988 (87) the application of SGUS for pSS has increased in 
both research studies and clinical work (53-55, 61, 63, 74). The imaging modality is 
non-invasive, can be considered low-cost compared to other currently available 
imaging techniques, but is highly user-dependent, which contributes to the diagnostic 
evaluation (53, 55). Regarding pSS, one major challenge is the multitude of scoring 
systems suggested in the literature (73, 75), all with separate advantages. Important 
aspects from our point of view were short operation time and easy application in the 
clinic. For the papers in this thesis, one of the less complex scoring systems mainly 
focusing on homogeneity and echogenicity was applied. Other studies have since 
confirmed the reliability of this approach (74, 77, 78).  
Our evaluation methodology evolved during the course of the project. In Paper I, we 
only used post-examination evaluation of still-images, whilst in Paper II and Paper 
III we performed a bedside evaluation. At the start of patient SGUS examinations for 
Paper I, both main investigators (DH and MVJ) were still learning the technique. 
Although in reality we did evaluate the SGUS examination bedside, we considered 
the scoring process for Paper I to be more reliable as post-examination evaluation. 
Also, Paper I was the first step to congregate images for documentation, later 
evaluation and comparison. In Paper III we combined both bedside evaluation and 
post-examination evaluation of images, with the addition of videos.   
In retrospect, a more ideal design in Paper I could have contained a record of the 
scoring done bedside, in addition to the scoring of digitally stored images. When 
performing the SGUS for Paper II, technical challenges limited the possibility for 





52/67 (78%) for later re-evaluation. In a pilot study presented as a poster at the ACR  
Annual meeting in 2017 (88), we found that we classified images as containing 
pathologic changes (grade 2-3) more often than we did bedside (Figure 7).  
 
 
Figure 7. A pilot study presented as a poster at ACR 2017 demonstrating a higher 
degree of pathological classification of SGUS findings in still-images compared to 
bedside (88).  
 
Different US machines were also used at the various centers (Paper II). Also, at two 
centers (The Netherlands and the USA), local specialists and not the main 





similar, high-grade US machines, and in discussion agree on SGUS scores, these two 
factors might have influenced the results. In general, the hardware used was of good 
quality and produced high-quality images. Variation in image contrast and resolution 
were noted, which might influence the ability to spot early, minuscule changes. With 
regard to different examiners, interrater correlations have been reported good to 
excellent between experts when using a simplified scoring system focusing on 
homogeneity and hypoechogenic areas (89).   
In Paper III, we performed both a bedside evaluation and evaluation and scoring of 
images/videos. The main limitation to this methodology was that only one of the 
three investigators performed the bedside examination, evaluation and image and 
video acquisition. Ideally, one could argue that all three should have conducted the 
bedside evaluation twice per patient to define the gold standard, as well as scoring the 
images and videos. The evaluation of images and videos was performed in a random 
order, blinded for patient identity and characteristics. We evaluated the images and 
videos on two separate occasions, two months apart (November 2017 and January 
2018). The first evaluation was used to compare our evaluation of images and videos 
to the gold standard and each other (interobserver). The second evaluation was used 
to compare re-evaluation (intraobserver).  
  
12.2 Study population 
In Paper I, the cohort studied consisted of well-characterized pSS patients that all 
fulfilled the AECG classification criteria (10). The patients were recruited from the 
Department of Rheumatology at Haukeland University Hospital, Bergen, Norway. 
Being recruited from a university hospital clinic, it is possible that the patients with 
low disease activity and not needing follow-up by a specialist might be 





disease profile. The cohort characteristics were however similar to other studies (90, 
91).  
In Paper II, the cohort consisted of younger patients recruited from three continents, 
five countries and eight hospitals. The included patients had previously received the 
jSS diagnosis by a pediatrician or specialist in rheumatology. The patients were 
younger than 18 years at the time of jSS diagnosis and not older than 25 years when 
included in the study. The age-limits were set to include both children and adolescent 
with pSS and to exclude patients with long standing disease. Exclusion criteria were 
currently known viral diseases (CMV, EBV, Hepatitis C, HIV), current eating 
disorders (bulimia and anorexia nervosa) or substance abuse (alcohol). Patients 
considered to have a disease profile more concurring with other connective tissue 
disorders such as SLE, without an associated jSS, were excluded from the cohort.  
When planning Paper II, lack of established diagnostic and classification criteria for 
jSS presented a major challenge. The disease manifestations of jSS are in some cases 
difficult to distinguish from other connective tissue diseases or IgG4 related 
conditions (92). Inclusion of patients from several continents also introduced possible 
genetic influences and environmental variations. Juvenile SS is however, a rare 
condition and too a rigorous patient selection, without established standardization or 
criteria to rely on, would probably have yielded too few patients compared to what 
was needed for a representative and sizeable cohort. As stated in several papers (34, 
50, 52), verified classification and diagnostic criteria are vital to improve patient 
selection in future studies.  
In Paper II, studying children and adolescents, we took on a non-invasive approach. 
Suggested jSS criteria (Table 3)(34) include five items (Items 7-11) based on 
laboratory tests. We did not have ethical approval to perform invasive procedures 





patients’ medical history. Consequently, we did not base our inclusion of jSS patients 
was on these criteria.   
For the benefit of this thesis, however, the implementation of previously suggested 
criteria for jSS was assessed retrospectively for the cohort in Paper II (Table 5). In 
the immediate data available, seven items at the most could be evaluated (Table 3 and 
5, items 1, 2, 4, 5, 6, 11, 12).  
For item 2, we applied AECG item I (Ocular dryness symptoms), which is based on 
daily, persistent, troublesome dry eyes for more than 3 months and/or recurrent 
sensation of sand or gravel in the eyes and/or tear substitutes more than 3 times a day. 
This criteria was fulfilled by 42/67 patients. 
In addition, for Item 2 we supplemented with xerostomia, AECG item II (Oral 
dryness symptoms), which is based on daily feeling of dry mouth for more than 3 
months, recurrent or persistent swollen salivary glands or the need to frequently drink 
liquids to aid in swallowing dry food. This item was noted in 48/66 patients. 
Seventeen of these patients did not fulfill item 2 based on AECG item I alone. 
Altogether, 59 patients fulfilled the supplemented item 2. 
Item 5, which is ocular dryness, was based on AECG item III (Ocular signs) and 
ACR/EULAR item 3; Schirmer’s I-test and Ocular staining score (OSS), or 
Schirmer’s I-test alone; only three patients had not performed any of these tests.  
For item 6, sialography, we also added ACR/EULAR item 5 and AECG item V 
(hyposalivation by unstimulated sialometry; UWS). Only three patients had 
performed sialography, whereof one was positive. UWS was positive in 20/60 
patients. 
For item 11, AECG item VI (Antibodies to Ro/SSA and/or La/SSB) and 





anti-Ro/SSA, anti-La/SSB, RF and ANA, except two patients who lacked RF titers. 
We had however no information on exact ANA-titers, only positive/negative. For 
13/63 patients, a positive ANA was the only test to fulfill item 11.  
Out of the seven possible items we were able to obtain data for, any one patient had 
data available for three to seven items. When applied, 30/67 patients had at least four 
positive items (Table 5), which is considered suggestive of jSS (34). This frequency 
is lower than 39/67 attained with the ACR/EULAR (17) and 35/67 with the AECG 
classification criteria (10). For the jSS criteria (34), the presence of other autoimmune 
diseases is an exclusion criterion. In our cohort, eleven patients had a prior diagnosis 
of MCTD, SLE or thyroid disease, with a concomitant SS-like disease profile.  
The addition of xerostomia to item 2 increased the number of patients fulfilling the 
jSS criteria with additionally five. If applying SGUS+ as an item to the jSS criteria, 
eleven additional patients fulfilled at least four items. Adding SGUS alone thus 
provided a diagnosis of jSS in 41/67 patients, which is slightly higher compared to 
the number of patients fulfilling the AECG and/or ACR/EULAR criteria. Xerostomia 
and SGUS together makes the number of patients fulfilling the criteria 45/67. 
Most of the patients had not performed a sialography (item 6), and substituting 
sialography with ACR/EULAR item 5 (hyposalivation by unstimulated sialometry; 
UWS), did indeed add four more patients that fulfilled the jSS criteria (34). Of note, 
reference values for UWS (Table 5) are based on levels for adults (81, 82). For 
children and adolescents, published UWS levels seem to vary depending on age, 
gender, and body composition, as well as health and climate (93, 94).  
Taking all alterations to the criteria (xerostomia, hyposalivation and SGUS+) into 
consideration, in total 50/67 patients would fulfill the jSS criteria, which is more than 
both the AECG and the ACR/EULAR classification criteria. Among the 50 patients, 





Five patients however, fulfilled either the AECG or the ACR/EULAR classification 
criteria, but not the jSS criteria. Twelve patients fulfilled neither criteria. Of these 
twelve patients, seven were SGUS+. They had however not performed sialography or 
sialoscintigraphy. Only one had a low UWS, three had sicca symptoms and none had 
a positive Schirmer’s I-test. Two had performed OSS, which were negative. All were 
anti-Ro/SSA+. 
Including sialoscintigraphy to item 6, as well as UWS and sialography, would add 
eight more patients fulfilling four items of the jSS criteria (34). Involving ionizing 
radiation, sialoscintigraphy is not a preferred imaging technique to perform in 
children without carefully considering its justification. Including sialoscintigraphy in 
jSS diagnostic/classification criteria would thus be inappropriate. 
The applied modification to the jSS criteria, with several added items could indeed 
render the cut-off of four items invalid. Nonetheless, it does imply that several 
symptoms, clinical findings and examinations should be considered when forming 
future jSS criteria.  
For Paper III, we included consecutive pSS patients with a clinical diagnosis of SS, 
regardless of whether they did or did not fulfill the AECG (10) or ACR/EULAR (17) 
classification criteria for pSS. The patient characteristics per se most likely did not 
influence the evaluation of images and videos, but the number of patients with 
pathological SGUS changes were lower in Paper III (sensitivity 43.8%) than in 
Paper I-II (sensitivity 52.6-61.2%). It is possible that this lower frequency of 
pathological findings (grade 2-3), and thus a higher frequency of normal findings or 







Table 5. Application of modified jSS criteria in the cohort from Paper II.   
Criteria item N 
1 Recurrent parotitis or parotid enlargement 37/58 
2 Recurrent conjunctivitis (non-allergic and non-infectious), or 
keratoconjunctivitis sicca 
42/67 
2+ Xerostomia 48/66 
3 Recurrent vaginitis Md 
4 Systemic: fever of unknown origin, arthralgias, hypokalemic 
paralysis, or abdominal pain 
24/59 
5 Ocular dryness (ocular staining or Schirmer I-test) 34/64 
6 Abnormal sialography 1/3 
6# Salivary gland involvement/Hyposalivation/UWS* 20/60 
7 Elevated serum amylase Md 
8 Leukopenia or elevated ESR Md 
9 Hyperimmunoglobulinaemia (polyclonal) Md 
10 Renal tubular acidosis Md 
11 At least one of: anti-Ro/SSA, anti-La/SSB, high titer ANA 
(speckled pattern), RF 
63/67 
12 Lymphocytic infiltration of minor labial salivary glands or other 
organs 
28/34 
 SGUS 41/67 
 AECG criteria 35 
 ACR/EULAR criteria 39 
 jSS criteria 30 
 jSS criteria xerostomia, UWS and SGUS 50 
+Xerostomia added to item 2, #UWS added to item 6, *UWS based on reference 








In Paper I, statistical methods were applied as described in section 10.7. In Paper II 
we applied Benjamin-Hochberg adjustment to reduce the false discovery rate (FDR) 
caused by multiple comparisons. Multiple comparisons increase the risk of significant 
findings being by chance and thus representing false positives. In Paper III, we used 
inter- and intracorrelation coefficient (ICC), obtaining intervals of numbers 
describing how strongly units within the same group, or between groups, resemble 
each other. 
 
12.4 Data collection 
Data collection for Paper I at the time of inclusion encompassed results from clinical 
examination including SGUS of both parotid and submandibular glands, unstimulated 
and stimulated sialometry, Schirmer’s I-test, blood samples/serology, and the patients 
up-dated medical history. For the patients with a previous diagnosis of pSS (n=82) 
retrospective data such as autoantibody profile (Ro/SSA, La/SSAB, RF) and minor 
salivary gland focus score were obtained from the patients charts. For the newly 
diagnosed patients (n=15), autoantibody profiles were determined at inclusion, and 
minor salivary gland biopsies performed in cases where the diagnosis otherwise could 
not be determined.  
Paper II was an explorative cross-sectional study including children and adolescents. 
Therefore, we wanted to minimize the number of invasive procedures such as blood 
tests, minor salivary gland biopsies and other imaging modalities, unless they were 
part of the clinical evaluation or follow-up of the individual patient. Historical 
laboratory tests, minor salivary gland biopsy results, and imaging findings from the 





from the patients’ medical journals. Patients had been evaluated at different hospitals 
in different cities, countries and continents, with differences in health care systems, 
diagnostic policies and treatment strategies. During plotting and analysis of data, 
some regional differences surfaced, which could have, had the data been interpreted 
separately, provided different results than the ones obtained for the cohort as a whole. 
SGUS findings were considerably more frequent in jSS patients recruited from 
Europe and the USA compared to Brazil. This important observation confirms how 
essential international collaborations are, in order to secure inclusion of a sizeable 
and representative cohort of patients and reduce confounding factor caused by 
regional differences when studying rare conditions such as jSS.  
Clinical examination including SGUS examination and evaluation, unstimulated 
sialometry and Schirmer’s I-test were performed upon inclusion. Other experts than 
the main investigators (DH, MVJ) examined the patients from the Netherlands and 
the USA.  
Paper III was a cross-sectional study and all clinical data and material, except for 
minor salivary gland biopsy results, were collected upon inclusion. When planning 
Paper III in 2017, the most recent ACR/EULAR classification criteria (17) had 
recently been published and we chose to apply these criteria in favor of the previously 
applied AECG classification criteria of 2002 (79). The two sets of classification 






12.5 Clinical considerations 
The use of SGUS in pSS was first described in 1988 (87). Considering the number of 
papers available on the subject, it is safe to say that the interest has gradually 
increased. In Paper I, we showed a significant connection between SGUS and clinical 
findings such as autoantibodies, unstimulated and stimulated salivary secretion, tear 
secretion, and sicca symptoms. We also applied a simplified scoring system, focusing 
on homogeneity and hypoechogenic areas. Since we published Paper I, other studies 
have confirmed that homogeneity and hypoechogenic areas are the most important 
items to evaluate in SGUS (78) and the connection to clinical findings (75, 77, 95). 
We demonstrated that patients that were both anti-Ro/SSA and anti-La/SSB positive 
were more likely to be SGUS+ compared to patients that were only anti-Ro/SSA 
positive. We also demonstrated that patients that were both anti-Ro/SSA and anti-
La/SSB negative were highly unlikely to be SGUS+.  
The inverse correlation between SGUS score and age (Paper I) lead to our interest in 
the rare, juvenile form of SS, jSS, affecting children and adolescents. Our working 
hypothesis was that SGUS changes are more prominent in jSS (Paper II). SGUS had 
previously been investigated in jSS (35, 96, 97), but only in smaller cohorts. 
In Paper II we have to date the largest cohorts investigating SGUS in jSS. The study 
was an explorative, cross-sectional study and a first step to investigate the correlation 
between SGUS, patients’ symptoms, clinical findings and existing classification 
criteria for pSS (10, 17). In this thesis, the suggested criteria for jSS were also applied 
(34) (Table 3 and 6). In line with findings in pSS, we detected a correlation between 
autoantibodies and SGUS (95). Earlier observations of parotid swelling/parotitis in 
jSS (33-35) and systemic manifestations (30, 38) were also confirmed in Paper II.  
The prevalence of pathological SGUS changes was 61% in jSS (Paper II) compared 





initial hypothesis that jSS patients had more SGUS changes than pSS patients could 
therefore not be confirmed.  
In Paper II, we found a high degree of EGM, which is slightly higher compared to 
other studies (30, 38).Systemic treatment was frequent, most commonly HCQ. 
Interestingly, current HCQ treatment was more common in the SGUS- patients. 
Paper II is a cross-sectional study and not a prospective intervention study, and 
possibly confounding factors could explain this correlation. Nonetheless, it does 
invite to speculation whether HCQ could have a protective effect, preventing 
development of the salivary gland disease if applied early in the disease development.   
 
During SGUS examinations for Paper II, we could observe that some of the jSS 
patients displayed distinct, evenly distributed hypoechogenic areas throughout the 
whole salivary gland. The changes were clearly visible when scanning the whole 
gland, and prominent enough to qualify as grade 2. The changes were however, 
difficult to demonstrate when freezing the image, and thus to document. These 
observations raised the question of the more suitable storage media for post-
examination evaluation, tested out in the pilot project shown in Figure 6 and to Paper 
III.   
Previous studies have investigated interrater reliability for SGUS (74, 77). Paper III 
is to our knowledge the first study to compare bedside evaluation to both video and 
image post-examination evaluations. In Paper III, we could see a tendency that 
longitudinal video of the parotid gland provided results most similar results to 
bedside evaluation. Nonetheless, we still speculate that a video-recording of a 
thorough scan throughout the salivary gland provides more information, reduces the 
possibility for user-dependent errors, and is more likely to correlate with bedside 







In line with the aims of this thesis the following conclusions can be drawn: 
 Major salivary gland ultrasound findings in pSS patients correlate with several 
clinical and laboratory findings for both pSS and jSS.  
 The prevalence of SGUS+ seems similar in pSS and jSS.  
 Extraglandular manifestations and parotitis are common in jSS  
 Using a simplified scoring system, both inter- and intrarater correlations of 
SGUS are excellent for experienced examiners. 
 Longitudinal video of the parotid gland US tends to be the most reliable post-







14. FUTURE PERSPECTIVES 
Salivary gland US represents a potential useful tool in both diagnostic and prognostic 
evaluation, and monitoring of treatment efficiency (28, 29, 53, 56-58, 72, 75, 99). 
Pathological SGUS changes such as inhomogeneity and hypoechogenic areas are 
highly specific for pSS (57, 72). In my experience, learning to perform the SGUS 
examination on a patient and to identify clearly pathological changes applicable for 
clinical use only requires brief training, making SGUS a useful diagnostic tool for the 
salivary gland component in pSS and jSS. However, evaluation of minute details 
requires more extensive practice and experience. Furthermore, technical 
complications with anatomical variants, subcutaneous fat, and atrophic or fibrotic 
salivary glands may complicate image acquisition, as well as interpretation.  
Salivary gland US findings are associated with known clinical and laboratory 
findings typical for pSS such as systemic complications and ESSDAI, as well as skin 
vasculitis and salivary gland swelling, elevated autoantibody titers and GC-like 
structures in minor salivary gland biopsies (58, 75, 77, 95).  All these factors are 
indicative of a more severe disease profile and increased risk for complications, most 
severely the development of lymphoma (6, 8, 100) And in that regard, SGUS 
represents a useful tool also for prognostic considerations (56). 
Some recent studies have demonstrated a slight improvement of SGUS findings 
following treatment with rituximab (28, 29), but the observations were not 
convincing enough to determine whether SGUS is a reliable tool to measure local 
treatment effect. The lack of established and reliable outcome measures is indeed a 
challenge for the SS research community. However, efforts to establish suitable tools 
are addressed in in the recently initiated EU H2020 Innovative Medicines Initiative 
(IMI2-2017-12-03 NECESSITY, Contract #806975) a collaboration between EU, the 





Before we can use SGUS as a tool for monitoring disease progression or remission, 
we need to determine the natural development of SGUS changes in SS. 
Autoantibodies, important biomarkers in pSS occur several years before disease onset 
(101) and suggest that the inflammatory changes occurring in the major and minor 
salivary glands also have a pre-clinical phase (Figure 8). In order to predict a possible 
therapeutic window and reverse disease pathogenesis and salivary gland destruction, 
it is crucial that we establish when such changes start to occur and the period before 
inflammatory changes develop into irreversible tissue damage.  
Previous studies have attempted to define this moment in disease pathogenesis. To 
our knowledge, only one study has included SGUS evaluation. Briefly, two SGUS 
analyses were performed with a mean time of 1.9 years apart (102), but no significant 
changes could be determined in the assessed parameters. It is possible that the 
patients included already had developed subclinical disease changes prior to 
diagnosis. More likely, the first SGUS examination and the follow-up were not long 
enough apart in time. With regard to results presented in this thesis (Papers I-III), it is 
also possible that jSS patients (Paper II) are more likely to have early stage 
inflammatory changes rather than actual tissue damage. The disease in adult patients 
often has a longer subclinical phase, with a delay from disease onset to diagnosis, 
possibly causing more extensive tissue damage. Early or minute changes are difficult 
to document in the SGUS images. The inverse correlation between SGUS changes 
and age we found in Paper I could suggest that patients diagnosed at an earlier age 
have a more severe disease profile, and therefore demonstrate a higher degree of 
pathological SGUS changes. The results from Paper III confirm the subjective 
contribution possibly depending on the clinical investigators training and experience.  
In the future, automatic image analysis could be an instrumental tool to detect minute 
SGUS changes and monitor disease progression – or remission. Long-term studies of 





addressing the natural history of the salivary gland component in SS. A prospective 
study would ideally examine newly diagnosed SS patients, where the period from 
first symptom to inclusion is short. Hypothetically, the SGUS changes would then 
mainly represent reversible inflammatory lesions rather than actual tissue damage. 
Standardized SGUS examinations performed over time, evaluated using automated 
image analysis would also provide data crucial for objective studies of treatment 
outcomes. Targeted treatment of susceptible patients early in their disease could 
result in remission of the salivary gland disease in SS, which would be possible to 




Figure 8. Suggested timeline for development of SGUS changes in pSS/jSS. Figure 







1. Jonsson R, Bowman SJ, Gordon TP. Sjögren's syndrome. In: Koopman WJ, editor. 
Arthritis and Allied Conditions. 15th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. 
p. 1681-705. 
2. Mengshoel AM, Norheim KB, Omdal R. Primary Sjögren's syndrome: fatigue is an 
ever-present, fluctuating, and uncontrollable lack of energy. Arthritis Care Res (Hoboken). 
2014;66(8):1227-32. 
3. Flores-Chavez A, Kostov B, Solans R, Fraile G, Maure B, Feijoo-Masso C, et al. 
Severe, life-threatening phenotype of primary Sjögren's syndrome: clinical characterisation 
and outcomes in 1580 patients (GEAS-SS Registry). Clinical and experimental 
rheumatology. 2018;36 Suppl 112(3):121-9. 
4. Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, et al. Primary 
Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical 
presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford). 
2014;53(5):839-44. 
5. Ramos-Casals M, Brito-Zeron P, Solans R, Camps MT, Casanovas A, Sopena B, et 
al. Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS 
disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 
(Oxford). 2014;53(2):321-31. 
6. Johnsen SJ, Brun JG, Göransson LG, Smastuen MC, Johannesen TB, Haldorsen K, et 
al. Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based 
study. Arthritis Care Res (Hoboken). 2013;65(5):816-21. 
7. Sutcliffe N, Inanc M, Speight P, Isenberg D. Predictors of lymphoma development in 
primary Sjögren's syndrome. Seminars in arthritis and rheumatism. 1998;28(2):80-7. 
8. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. 
Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer 
incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796-803. 
9. Delli K, Villa A, Farah CS, Celentano A, Ojeda D, Peterson D, et al. World 
Workshop on Oral Medicine VII: Biomarkers predicting lymphoma in the salivary glands of 
patients with Sjögren's syndrome. A systematic review. Oral diseases. 2019. 
10. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, 
et al. Classification criteria for Sjögren's syndrome: a revised version of the European 
criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 
2002;61(6):554-8. 
11. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmström P, Wahren-
Herlenius M, et al. Cellular basis of ectopic germinal center formation and autoantibody 
production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum. 
2003;48(11):3187-201. 
12. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, et al. 
Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the 
development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum 
Dis.70(8):1363-8. 
13. Sene D, Ismael S, Forien M, Charlotte F, Kaci R, Cacoub P, et al. Ectopic Germinal 





Occurrence in Patients With Primary Sjögren's Syndrome. Arthritis Rheumatol. 
2018;70(9):1481-8. 
14. Haacke EA, van der Vegt B, Vissink A, Spijkervet FKL, Bootsma H, Kroese FGM. 
Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's 
syndrome are not predictive for parotid MALT lymphoma development. Ann Rheum Dis. 
2017;76(10):1781-4. 
15. Delaleu N, Mydel P, Brun JG, Jonsson MV, Alimonti A, Jonsson R. Sjögren's 
syndrome patients with ectopic germinal centers present with a distinct salivary proteome. 
Rheumatology (Oxford). 2016;55(6):1127-37. 
16. Delaleu N, Mydel P, Kwee I, Brun JG, Jonsson MV, Jonsson R. High fidelity 
between saliva proteomics and the biologic state of salivary glands defines biomarker 
signatures for primary Sjögren's syndrome. Arthritis Rheumatol. 2015;67(4):1084-95. 
17. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 
2016 American College of Rheumatology/European League Against Rheumatism 
classification criteria for primary Sjögren's syndrome: A consensus and data-driven 
methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9-
16. 
18. Askanase AD, Friedman DM, Copel J, Dische MR, Dubin A, Starc TJ, et al. 
Spectrum and progression of conduction abnormalities in infants born to mothers with anti-
SSA/Ro-SSB/La antibodies. Lupus. 2002;11(3):145-51. 
19. Eliasson H, Sonesson SE, Sharland G, Granath F, Simpson JM, Carvalho JS, et al. 
Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study 
of 175 patients. Circulation. 2011;124(18):1919-26. 
20. Miyasato-Isoda M, Waguri M, Yamada Y, Miyano A, Wada Y. Anti-Ro52 antibody 
level is an important marker of fetal congenital heart block risk in anti-Ro/SSA antibody 
positive pregnancy. Modern rheumatology. 2018;28(4):690-6. 
21. Xue D, Shi H, Smith JD, Chen X, Noe DA, Cedervall T, et al. A lupus-like syndrome 
develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proceedings of 
the National Academy of Sciences of the United States of America. 2003;100(13):7503-8. 
22. Gøransson LG, Haldorsen K, Brun JG, Harboe E, Jonsson MV, Skarstein K, et al. 
The point prevalence of clinically relevant primary Sjögren's syndrome in two Norwegian 
counties. Scand J Rheumatol. 2011;40(3):221-4. 
23. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary 
Sjögren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 
2015;74(11):1983-9. 
24. Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome. 
Nature reviews Rheumatology. 2016;12(8):456-71. 
25. Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of 
hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the 
JOQUER randomized clinical trial. Jama. 2014;312(3):249-58. 
26. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, 
Puechal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. 
Annals of internal medicine. 2014;160(4):233-42. 
27. Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, et al. 





Fatigue and Oral Dryness in Primary Sjögren's Syndrome. Arthritis Rheumatol. 
2017;69(7):1440-50. 
28. Fisher BA, Everett CC, Rout J, O'Dwyer JL, Emery P, Pitzalis C, et al. Effect of 
rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the 
TRACTISS randomised double-blind multicentre substudy. Ann Rheum Dis. 
2018;77(3):412-6. 
29. Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, Marhadour T, Bressollette L, 
Gestin S, et al. Brief Report: Ultrasonographic Assessment of Salivary Gland Response to 
Rituximab in Primary Sjögren's Syndrome. Arthritis Rheumatol. 2015;67(6):1623-8. 
30. Anaya JM, Ogawa N, Talal N. Sjögren's syndrome in childhood. The Journal of 
rheumatology. 1995;22(6):1152-8. 
31. Lieberman SM. Childhood Sjögren syndrome: insights from adults and animal 
models. Current opinion in rheumatology. 2013;25(5):651-7. 
32. O'Neill EM. Sjögren's syndrome with onset at 10 years of age. Proceedings of the 
Royal Society of Medicine. 1965;58(9):689-90. 
33. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary 
Sjögren syndrome in the paediatric age: a multicentre survey. European journal of pediatrics. 
2003;162(10):661-5. 
34. Bartunkova J, Sediva A, Vencovsky J, Tesar V. Primary Sjögren's syndrome in 
children and adolescents: proposal for diagnostic criteria. Clinical and experimental 
rheumatology. 1999;17(3):381-6. 
35. Fang QG, Liu FY, Sun CF. Recurrent submandibular gland swelling as a first 
manifestation in a child with primary Sjögren syndrome. The Journal of craniofacial surgery. 
2013;24(4):e413-5. 
36. Nikitakis NG, Rivera H, Lariccia C, Papadimitriou JC, Sauk JJ. Primary Sjögren 
syndrome in childhood: report of a case and review of the literature. Oral surgery, oral 
medicine, oral pathology, oral radiology, and endodontics. 2003;96(1):42-7. 
37. Bogdanovic R, Basta-Jovanovic G, Putnik J, Stajic N, Paripovic A. Renal 
involvement in primary Sjögren syndrome of childhood: case report and literature review. 
Modern rheumatology. 2013;23(1):182-9. 
38. Virdee S, Greenan-Barrett J, Ciurtin C. A systematic review of primary Sjögren's 
syndrome in male and paediatric populations. Clinical rheumatology. 2017;36(10):2225-36. 
39. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et 
al. American College of Rheumatology classification criteria for Sjögren's syndrome: A 
data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical 
Alliance Cohort. Arthritis Care Res. 2012;64(4):475–87. 
40. Tsuboi H, Hagiwara S, Asashima H, Takahashi H, Hirota T, Noma H, et al. 
Comparison of performance of the 2016 ACR-EULAR classification criteria for primary 
Sjögren's syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis. 
2017;76(12):1980-5. 
41. T. O. Sjögren’s Disease Research Committee review on research reports: annual 
report of the Ministry of Health and Welfare. Tokyo: Japanese Ministry of Health. 1977. 
42. Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren's syndrome. Proposed 





43. Homma M, Tojo T, Akizuki M, Yamagata H. Criteria for Sjögren's syndrome in 
Japan. Scandinavian journal of rheumatology Supplement. 1986;61:26-7. 
44. Manthorpe R, Oxholm P, Prause JU, Schiodt M. The Copenhagen criteria for 
Sjögren's syndrome. Scandinavian journal of rheumatology Supplement. 1986;61:19-21. 
45. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein 
RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a 
prospective concerted action supported by the European Community. Arthritis Rheum. 
1993;36(3):340-7. 
46. Miyawaki S. [Revised Japan criteria for Sjögren syndrome]. Ryumachi 
[Rheumatism]. 2000;40(1):48-53. 
47. Le Goff M, Cornec D, Jousse-Joulin S, Guellec D, Costa S, Marhadour T, et al. 
Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value 
of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren's 
syndrome. Arthritis Res Ther. 2017;19(1):269. 
48. Schuetz C, Prieur AM, Quartier P. Sicca syndrome and salivary gland infiltration in 
children with autoimmune disorders: when can we diagnose Sjögren syndrome? Clinical and 
experimental rheumatology. 2010;28(3):434-9. 
49. Yokogawa N, Lieberman SM, Alawi F, Bout-Tabaku S, Guttenberg M, Sherry DD, 
et al. Comparison of labial minor salivary gland biopsies from childhood Sjögren syndrome 
and age-matched controls. The Journal of rheumatology. 2014;41(6):1178-82. 
50. Houghton K, Malleson P, Cabral D, Petty R, Tucker L. Primary Sjögren's syndrome 
in children and adolescents: are proposed diagnostic criteria applicable? The Journal of 
rheumatology. 2005;32(11):2225-32. 
51. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 
2016 American College of Rheumatology/European League Against Rheumatism 
classification criteria for primary Sjögren's syndrome: A consensus and data-driven 
methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9-
16. 
52. Yokogawa N, Lieberman SM, Sherry DD, Vivino FB. Features of childhood 
Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in 
establishing child-specific diagnostic criteria. Clinical and experimental rheumatology. 
2016;34(2):343-51. 
53. Zengel P, Schrotzlmair F, Reichel C, Paprottka P, Clevert DA. Sonography: the 
leading diagnostic tool for diseases of the salivary glands. Semin Ultrasound CT MR. 
2013;34(3):196-203. 
54. Riente L, Delle Sedie A, Filippucci E, Iagnocco A, Meenagh G, Epis O, et al. 
Ultrasound imaging for the rheumatologist XIV. Ultrasound imaging in connective tissue 
diseases. Clinical and experimental rheumatology. 2008;26(2):230-3. 
55. Mossel E, Delli K, van Nimwegen JF, Stel AJ, Kroese FGM, Spijkervet FKL, et al. 
Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and 
classification criteria in patients with clinically suspected primary Sjögren's syndrome. Ann 
Rheum Dis. 2017;76(11):1883-9. 
56. Fidelix T, Czapkowski A, Azjen S, Andriolo A, Trevisani VFM. Salivary gland 






57. Baldini C, Luciano N, Tarantini G, Pascale R, Sernissi F, Mosca M, et al. Salivary 
gland ultrasonography: a highly specific tool for the early diagnosis of primary Sjögren's 
syndrome. Arthritis Res Ther. 2015;17:146. 
58. Theander E, Mandl T. Primary Sjögren's syndrome: diagnostic and prognostic value 
of salivary gland ultrasonography using a simplified scoring system. Arthritis Care Res 
(Hoboken). 2014;66(7):1102-7. 
59. Jousse-Joulin S, Gatineau F, Baldini C, Baer AN, Barone F, Bootsma H, et al. 
Modification of the Classification Criteria for Primary Sjögren Syndrome: An International 
Vignette Survey. ACR 2017. 2017;ACR abstract number: 877. 
60. Takagi Y, Nakamura H, Sumi M, Shimizu T, Hirai Y, Horai Y, et al. Combined 
classification system based on ACR/EULAR and ultrasonographic scores for improving the 
diagnosis of Sjögren's syndrome. PloS one. 2018;13(4):e0195113. 
61. Salaffi F, Carotti M, Iagnocco A, Luccioli F, Ramonda R, Sabatini E, et al. 
Ultrasonography of salivary glands in primary Sjögren's syndrome: a comparison with 
contrast sialography and scintigraphy. Rheumatology (Oxford). 2008;47(8):1244-9. 
62. El Miedany YM, Ahmed I, Mourad HG, Mehanna AN, Aty SA, Gamal HM, et al. 
Quantitative ultrasonography and magnetic resonance imaging of the parotid gland: can they 
replace the histopathologic studies in patients with Sjögren's syndrome? Joint Bone Spine. 
2004;71(1):29-38. 
63. Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, Guias B, Pennec Y, Pers JO, et al. 
Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome 
treated with rituximab: Quantitative and Doppler waveform analysis. Biologics. 
2007;1(3):311-9. 
64. Shimizu M, Okamura K, Yoshiura K, Ohyama Y, Nakamura S. Sonographic 
diagnosis of Sjögren syndrome: evaluation of parotid gland vascularity as a diagnostic tool. 
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 
2008;106(4):587-94. 
65. Ophir J, Cespedes I, Ponnekanti H, Yazdi Y, Li X. Elastography: a quantitative 
method for imaging the elasticity of biological tissues. Ultrasonic imaging. 1991;13(2):111-
34. 
66. Samier-Guerin A, Saraux A, Gestin S, Cornec D, Marhadour T, Devauchelle-Pensec 
V, et al. Can ARFI elastometry of the salivary glands contribute to the diagnosis of Sjögren's 
syndrome? Joint Bone Spine. 2016;83(3):301-6. 
67. Zhang S, Zhu J, Zhang X, He J, Li J. Assessment of the Stiffness of Major Salivary 
Glands in Primary Sjögren's Syndrome through Quantitative Acoustic Radiation Force 
Impulse Imaging. Ultrasound in medicine & biology. 2016;42(3):645-53. 
68. Jousse-Joulin S, Devauchelle-Pensec V, Morvan J, Guias B, Pennec Y, Pers JO, et al. 
Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome 
treated with rituximab: Quantitative and Doppler waveform analysis. Biologics. 
2007;1(3):311-9. 
69. Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, et al. Towards 
personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology 
predicts responsiveness to rituximab treatment. Ann Rheum Dis. 2016;75(11):1933-8. 
70. Delli K, Haacke EA, Kroese FG, Pollard RP, Ihrler S, van der Vegt B, et al. In 





glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI. Ann 
Rheum Dis. 2016;75(6):e34. 
71. Pijpe J, Meijer JM, Bootsma H, van der Wal JE, Spijkervet FK, Kallenberg CG, et al. 
Clinical and histologic evidence of salivary gland restoration supports the efficacy of 
rituximab treatment in Sjögren's syndrome. Arthritis Rheum. 2009;60(11):3251-6. 
72. Hocevar A, Ambrozic A, Rozman B, Kveder T, Tomsic M. Ultrasonographic 
changes of major salivary glands in primary Sjögren's syndrome. Diagnostic value of a novel 
scoring system. Rheumatology (Oxford). 2005;44(6):768-72. 
73. Zhou M, Song S, Wu S, Duan T, Chen L, Ye J, et al. Diagnostic accuracy of salivary 
gland ultrasonography with different scoring systems in Sjögren's syndrome: a systematic 
review and meta-analysis. Scientific reports. 2018;8(1):17128. 
74. Jousse-Joulin S, Nowak E, Cornec D, Brown J, Carr A, Carotti M, et al. Salivary 
gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core 
items definition and reliability. RMD Open. 2017;3(1):e000364. 
75. Delli K, Dijkstra PU, Stel AJ, Bootsma H, Vissink A, Spijkervet FK. Diagnostic 
properties of ultrasound of major salivary glands in Sjögren's syndrome: a meta-analysis. 
Oral diseases. 2015;21(6):792-800. 
76. De Vita S, Lorenzon G, Rossi G, Sabella M, Fossaluzza V. Salivary gland 
echography in primary and secondary Sjögren's syndrome. Clinical and experimental 
rheumatology. 1992;10(4):351-6. 
77. Delli K, Arends S, van Nimwegen JF, Dijkstra PU, Stel AJ, Spijkervet FKL, et al. 
Ultrasound of the Major Salivary Glands is a Reliable Imaging Technique in Patients with 
Clinically Suspected Primary Sjögren's Syndrome. Ultraschall in der Medizin (Stuttgart, 
Germany : 1980). 2018;39(3):328-33. 
78. Mossel E, Arends S, van Nimwegen JF, Delli K, Stel AJ, Kroese FGM, et al. Scoring 
hypoechogenic areas in one parotid and one submandibular gland increases feasibility of 
ultrasound in primary Sjögren's syndrome. Ann Rheum Dis. 2018;77(4):556-62. 
79. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, 
et al. Classification criteria for Sjögren's syndrome: a revised version of the European 
criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 
2002;61(6):554-8. 
80. Jonsson MV DN, Marthinussen MC, Jonsson R. Oral and dental manifestations of 
Sjögren’s syndrome – Current approaches to diagnostics and therapy.  Sjögren's syndrome: 
Pathogenesis and therapy New York, Dordrecht, Heidelberg, London: Springer2011. p. 221-
42. 
81. Jonsson MV RT, Delaleu ND, Marthinussen MC. Diagnostikk av munntørrhet og 
bruk av saliva som diagnostikk verktøy. Den Norske Tannlegeforenings Tidende 
2011;2011;121(14):908–13. 
82. Vissink A WA, Vermann ECI. Saliva Collectors. In: Wong DT, editor. Salivary 
Diagnostics2008. 
83. Jonsson R, Bolstad AI, Brokstad KA, Brun JG. Sjögren's syndrome--a plethora of 
clinical and immunological phenotypes with a complex genetic background. Annals of the 
New York Academy of Sciences. 2007;1108:433-47. 
84. Lee J, Koh JH, Kwok SK, Park SH. The EULAR Sjögren's Syndrome Patient-





patients with primary Sjögren's syndrome. Clinical and experimental rheumatology. 
2016;34(4):663-7. 
85. Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. 
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open. 
2015;1(1):e000022. 
86. Cicchetti DV. Guidelines, criteria, and rules of thumb for evaluating normed and 
standardized assessment instruments in psychology. Psychological Assessment. 1994(6 
(4)):284–90. 
87. Bradus RJ, Hybarger P, Gooding GA. Parotid gland: US findings in Sjögren 
syndrome. Work in progress. Radiology. 1988;169(3):749-51. 
88. Hammenfors DS VV, Pasoto SG, Lilleby V, Nieto JC, Silva C, Pereira RMR, Bica B, 
Brun JG, Jonsson R, Jonsson MV. Major Salivary Gland Ultrasonography Bed-Side and Still 
Image Scoring – a Pilot Comparison in Juvenile Sjögren’s Syndrome [abstract]. Arthritis 
Rheumatol. 2017;2017; 69 (suppl 10). https://acrabstracts.org/abstract/major-salivary-gland-
ultrasonography-bed-side-and-still-image-scoring-a-pilot-comparison-in-juvenile-Sjögrens-
syndrome/. 
89. Jousse-Joulin S, Nowak E, Cornec D, Brown J, Carr A, Carotti M, et al. Salivary 
gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core 
items definition and reliability. RMD Open. 2017;3(1):e000364. 
90. Brito-Zeron P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E, et al. 
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's 
syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren 
Project Consortium. Ann Rheum Dis. 2017;76(6):1042-50. 
91. Brito-Zeron P, Acar-Denizli N, Ng WF, Zeher M, Rasmussen A, Mandl T, et al. How 
immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: 
analysis of 10,500 patients (Sjögren Big Data Project). Clinical and experimental 
rheumatology. 2018;36 Suppl 112(3):102-12. 
92. Narayan AK, Baer A, Fradin J. Sonographic findings of IgG4-related disease of the 
salivary glands: Case report and review of the literature. Journal of clinical ultrasound : JCU. 
2018;46(1):73-7. 
93. Bretz WA, do Valle EV, Jacobson JJ, Marchi F, Mendes S, Nor JE, et al. 
Unstimulated salivary flow rates of young children. Oral surgery, oral medicine, oral 
pathology, oral radiology, and endodontics. 2001;91(5):541-5. 
94. Torres SR, Nucci M, Milanos E, Pereira RP, Massaud A, Munhoz T. Variations of 
salivary flow rates in Brazilian school children. Brazilian oral research. 2006;20(1):8-12. 
95. Nieto-Gonzalez JC, Ovalles-Bonilla JG, Estrada E, Serrano-Benavente B, Martinez-
Barrio J, Gonzalez-Fernandez CM, et al. Salivary gland ultrasound is linked to the 
autoimmunity profile in patients with primary Sjögren's syndrome. The Journal of 
international medical research. 2018:300060518767031. 
96. Nieto-Gonzalez JC, Monteagudo I, Bello N, Martinez-Estupinan L, Naredo E, 
Carreno L. Salivary gland ultrasound in children: a useful tool in the diagnosis of juvenile 
Sjögren's syndrome. Clin Exp Rheumatol. 2014;32(4):578-80. 
97. Civilibal M, Canpolat N, Yurt A, Kurugoglu S, Erdamar S, Bagci O, et al. A child 






98. Baldini C, Zabotti A, Filipovic N, Vukicevic A, Luciano N, Ferro F, et al. Imaging in 
primary Sjögren's syndrome: the 'obsolete and the new'. Clin Exp Rheumatol. 2018;36 Suppl 
112(3):215-21. 
99. Martire MV, Santiago ML, Cazenave T, Gutierrez M. Latest Advances in Ultrasound 
Assessment of Salivary Glands in Sjögren Syndrome. Journal of clinical rheumatology : 
practical reports on rheumatic & musculoskeletal diseases. 2018;24(4):218-23. 
100. Brito-Zeron P, Kostov B, Fraile G, Caravia-Duran D, Maure B, Rascon FJ, et al. 
Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. 
Journal of hematology & oncology. 2017;10(1):90. 
101. Theander E, Jonsson R, Sjostrom B, Brokstad K, Olsson P, Henriksson G. Prediction 
of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early 
Onset and Severe Disease Course by Autoantibody Profiling. Arthritis Rheumatol. 
2015;67(9):2427-36. 
102. Gazeau P, Cornec D, Jousse-Joulin S, Guellec D, Saraux A, Devauchelle-Pensec V. 
Time-course of ultrasound abnormalities of major salivary glands in suspected Sjögren's 




















Constitutional domain [3] 
Please be careful of not rating constitutional symptoms not related to the disease (such 
as fever of infectious origin, voluntary weight loss) 
No activity Absence of the following symptoms  
Low activity Mild or intermittent fever (37.5°-38.5°C) / night sweats  




Severe Fever (>38.5°C) / night sweats  




Lymphadenopathy domain [4] 
No activity Absence of the following features  





- Lymphadenopathy ≥ 2cm in any nodal region or ≥ 3cm in 
inguinal region,  
- and/or splenomegaly (clinically palpable or assessed by 
imaging) 
 







Glandular  domain [2] 
Please be careful of not rating glandular swelling not related to the disease (such as stone 
or infection)  
No activity Absence of glandular swelling  
Low activity Small glandular swelling with: 
- enlarged parotid (≤ 3cm),  




Major glandular swelling with: 
- enlarged parotid (>3cm ) 
- or important submandibular or lachrymal swelling1 
 
1Distinction between limited and important submandibular or lachrymal swelling is 
left to the physician judgment  
 
 
Articular domain [2] 
Please be careful of not rating articular involvement not related to the disease, such as 
osteoarthritis 
No activity Absence of currently active articular involvement  
Low activity Arthralgias in hands, wrists, ankles and feet accompanied by 




1 to 5 synovitis among a 28 count   







Cutaneous domain [3] 
Please be careful of rating as “No activity” stable long lasting features that are related 
to damage rather than disease activity, or cutaneous involvement not related to the 
disease 
No activity Absence of currently active cutaneous involvement  
Low activity Erythema multiforme  
Moderate 
activity 
Limited cutaneous vasculitis, including urticarial vasculitis2, 
or purpura limited to feet and ankle,  
or subacute cutaneous lupus  
 
High activity Diffuse cutaneous vasculitis, including urticarial vasculitis2, 
or diffuse purpura 
or ulcers related to vasculitis  
 
2 Limited cutaneous vasculitis involve <18% body surface area; Diffuse Cutaneous 
vasculitis involve >18% body surface area 
Body surface area (BSA) is defined using the rules of nines (used to assess extent of 
burns) as follows: Palm (excluding fingers) = 1% BSA; each lower limb = 18% BSA; 






Pulmonary domain [5] 
Please be careful of rating as “No activity” stable long lasting features that are related 
to damage rather than disease activity, or respiratory involvement not related to the 
disease, (tobacco…) 
No activity Absence of currently active pulmonary involvement  
Low activity Persistent cough or bronchial involvement with no radiographic 
abnormalities on X-ray 
Or radiological or HRCT evidence of interstitial lung disease3 
with:  
 No breathlessness, 




Moderately active pulmonary involvement, such as interstitial 
lung disease proven by HRCT3 with   
 shortness of breath on exercise (NHYA II)  
 or abnormal lung function tests restricted to: 
- 70% >DLCO ≥ 40% and/or 80% > FVC ≥ 60% 
 
High activity Highly active pulmonary involvement, such as interstitial lung 
disease proven by HRCT3 with : 
 shortness of breath at rest (NHYA III, IV) 
 or with abnormal lung function tests: 
- DLCO < 40% and/or FVC < 60% 
 
3For diagnosis of interstitial lung disease HRCT or radiography is required and must 
have been performed in the last 2 years 
DLCO= diffusing CO capacity; FVC= forced vital capacity; HRCT= high-resolution 






Renal domain [5] 
Please be careful of rating as “No activity” stable long lasting features that are related to 
damage rather than disease activity, and renal involvement not related to the disease.  
If biopsy has been performed, please rate activity based on histological features first. 
No activity 
Absence of currently active renal involvement: 
- Proteinuria< 0.5g/d, no hematuria, no leucocyturia, no 
acidosis. 
- Or long lasting stable proteinuria due to damage 
 
Low activity 
Evidence of specific active renal involvement, limited to: 
 Tubular acidosis without renal failure (GFR4 
≥60ml/min) 
 Glomerular involvement  
- with proteinuria (between 0.5 and 1 g/d)  




Moderately active renal involvement, such as: 
 Tubular acidosis with renal failure (GFR4 < 60 ml/min) 
 Glomerular involvement  
-   with proteinuria  between 1 and 1.5g/d 
-   without hematuria or renal failure (GFR4 ≥ 60ml/min) 
 or histological evidence of  
-  Extra-membranous glomerulonephritis 
-  Important interstitial lymphoid infiltrate 
 
High activity 
Highly active renal involvement, such as: 
 Glomerular involvement  
- with proteinuria > 1.5 g/d 
- or haematuria  
- or renal failure (GFR4 < 60 ml/min) 
  or histological evidence of  
- proliferative glomerulonephritis 
- cryoglobulinemia related renal involvement  
 






Muscular domain [6] 
Please be careful of not rating muscular involvement not related to the disease, such 
as weakness due to corticosteroids… 
No activity Absence of currently active muscular involvement  
Low activity Active myositis proven by abnormal EMG or biopsy with: 
- no weakness  




Moderately active myositis proven by abnormal EMG or 
biopsy with: 
- weakness (maximal deficit of 4/5), 
- or elevated creatinine kinase (2N < CK ≤ 4N),  
 
High activity Highly active myositis proven by abnormal EMG or biopsy 
with: 
- weakness (deficit ≤ 3/5) 








Peripheral nervous system domain [5] 
Please be careful of rating as “No activity” stable long lasting features that are related 
to damage rather than activity, or PNS involvement not related to the disease 
No activity Absence of currently active PNS involvement  
Low activity Evidence of active peripheral nervous system involvement, 
such as: 
- - Pure sensory axonal polyneuropathy proven by NCS 




Evidence of moderately active peripheral nervous system 
involvement shown by NCS, such as:  
- Axonal sensory-motor neuropathy with maximal 
motor deficit of 4/5,  
- Pure sensory neuropathy with presence of 
cryoglobulinemic vasculitis, 
- Ganglionopathy5 with symptoms restricted to 
mild/moderate ataxia,  
- Inflammatory demyelinating polyneuropathy6 (CIDP) 
with mild Functional impairment (maximal motor 
deficit of 4/5or mild ataxia), 
Or cranial nerve involvement of peripheral origin (except 
trigeminal (V) neuralgia) 
 
High activity Evidence of highly active peripheral nervous system 
involvement shown by NCS, such as:  
- Axonal sensory-motor neuropathy with motor deficit ≤ 
3/5 
- Peripheral nerve involvement due to vasculitis 
(mononeuritis multiplex, etc…) 
- Severe ataxia due to ganglionopathy5  
- Inflammatory demyelinating polyneuropathy6 (CIDP) 
with severe functional impairment: motor deficit ≤ 3/5 
or severe ataxia 
 
NCS: Nerve conduction studies. 
5 Pure sensory impairment with ataxia and diffuse impairment or abolition of 
sensitive potential on NCS 
6 Polyradiculoneuropathy with suggestive clinical symptoms (4 limbs sensorimotor 
deficit, proximal motor deficit, generalised areflexia, initial sensory symptoms 
affecting the upper limbs, and/or associated involvement of cranial nerves), increased 
protein level and/or supportive abnormal NCS (prolonged motor distal latency, 
reduced nerve conduction velocity, prolonged F wave latency, conduction block 






Central nervous system domain [5] 
Please be careful of rating as “No activity” stable long lasting features that are related to 
damage rather than disease activity, or CNS involvement not related to the disease 
No activity Absence of currently active CNS involvement  
Moderate 
activity 
Moderately active CNS features, such as: 
- Cranial nerve involvement of central origin 
- Optic neuritis 
- Multiple sclerosis-like syndrome with symptoms restricted to 
pure sensory impairment or proven cognitive impairment  
 
High activity Highly active CNS features, such as:  
- Cerebral vasculitis with  cerebrovascular accident or transient 
ischemic attack  
- Seizures 
- Transverse myelitis.  
- Lymphocytic meningitis 








Haematological  domain [2] 
Please be careful : 
- considering anemia7, thrombopenia8 and neutropenia9, only auto-immune cytopenia 
must be considered  
- not rating cytopenia not related to the disease ( such as vitamin or iron deficiency, drug-
induced cytopenia, as for example lymphocytopenia associated with cyclophosphamide) 
No activity Absence of auto-immune cytopenia  
Low activity Cytopenia of auto-immune origin with: 
- neutropenia (1000 < neutrophils < 1500/mm3) 
- or anemia (10 <  Hb  < 12g/dl) 
- or thrombocytopenia ( 100,000 < Plt < 150,000/mm3)  




Cytopenia of auto-immune origin with:  
- neutropenia (500 ≤ neutrophils  ≤  1000/mm3), 
- or anaemia (8 ≤ Hb  ≤ 10g/dl)  
- or thrombocytopenia (50,000 ≤ Plt  ≤ 100,000/mm3)  
Or lymphopenia (≤500/mm3) 
 
High activity Cytopenia of auto-immune origin with: 
- neutropenia (neutrophils < 500/mm3), 
- or anemia (Hb < 8 g/dl)  
- or thrombocytopenia (Plt < 50,000/mm3),  
 
7 Anaemia with positive Coombs testing and increase reticulocyte count 
8 Thrombopenia of peripheral origin with no other aetiology found, or in case of 
difficulty with anti-platelet autoantibodies and/or presence of megakaryocyte on bone 
marrow aspirate and/or associated autoimmune anaemia. 
9 Neutropenia with no other etiology found 
 
Biological domain [1] 
No activity Absence of any of the following biological features  
Low activity - Clonal component  
- or hypocomplementemia (low C4 or C3 or CH50)  





- presence of cryoglobulinemia  
- or hypergammaglobulinemia or high IgG level > 20g/L 
- or recent onset10 hypogammaglobulinemia or recent 
decrease of IgG level (<5g/L) 
 








- The score of each domain is the product of the weight of the domain by the 
level of activity. The domain weights are indicated in bracket for each domain. 
- Activity levels should be scored as follows: 
o No activity  = 0 
o Low activity  = 1 
o Moderate activity  = 2 
o High activity = 3 
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ABSTRACT 
Background/objectives: Ju e ile Sjögre ’s s dro e jSS  is a rare, poorl  defi ed a d 
possibly underdiagnosed condition affecting children/adolescents. The aim of this study was 
to characterize symptoms and clinical findings of jSS, and to explore the clinical application 
of major salivary gland ultrasonography (SGUS) in patients with jSS. 
Methods: A cross-sectional multicenter study recruited patients with disease onset until 18 
years of age (n=67). Disease characteristics were recorded, unstimulated whole sialometry 
and SGUS examination of the parotid and submandibular salivary glands was performed.  
Results: Female:male ratio was 58:9 (6.4:1). Mean age at first symptom was 10.2 years, 12.1 
years at diagnosis. Ocular and oral symptoms were noted in 42/67 (63%) and 53/66 (80%) 
patients, respectively. AECG or ACR-EULAR classification criteria for primary SS (pSS) was 
fulfilled by 42/67 (63 %) patients. Pathological SGUS findings (SGUS+) were observed in 
41/67 (61%) patients; 26/41 (63%) SGUS+ fulfilled pSS criteria. Salivary gland 
enlargements/parotitis was noted in 37/58 patients and non-significantly associated with 
SGUS+ (p=0.066).  Mean levels of saliva was 5.6 ml/15 minutes in SGUS- patients compared 
to 3.3 ml/15 minutes in the SGUS+ patients (p=0.049). 36/41 (88%) SGUS+ patients were 
anti-Ro/La+ compared to 14/26 (54%) SGUS- patients (p=0.001). 24/39 (62%) SGUS+ 
patients were RF+, whereas only 5/25 (20%) SGUS- patients were RF+ (p=0.001). 
Conclusions: Juvenile SS is characterized by a large spectrum of clinical symptoms and 
findings. Several glandular and extraglandular parameters such as hyposalivation, swollen 
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Significance and innovation:  
Interest for jSS is increasing and international collaborations are emerging. To date, this is 
the largest cohort world-wide characterizing juvenile Sjögren's syndrome and also the first 
large study investigating salivary gland ultrasonography in this patient group.  
 
INTRODUCTION 
Pri ar  Sjögre ’s s dro e pSS  is a systemic autoimmune disorder. Patients with pSS 
experience oral and ocular dryness and extraglandular manifestations (EGM) such as 
fatigue, arthralgia and arthritis (1). In addition to subjective and objective findings of salivary 
and/or lacrimal gland involvement, the pSS classification is based on either the presence of 
autoantibodies against Ro/SSA and/or La/SSB, and/or focal mononuclear cell inflammation 
with a focus score  1 in a minor labial salivary gland biopsy (2). Serum autoantibodies have 
been presented as early markers of pSS (3). 
Ju e ile Sjögre ’s s dro e jSS  is a rare, poorly defined and possibly underdiagnosed 
condition (4, 5). Mean age at time of diagnosis is around 10 years (6). A common initial 
symptom is swelling of the major salivary glands (6, 7). Several organ systems may be 
affected, resulting in neurological, dermatological, musculoskeletal, vascular, 
gastrointestinal, respiratory, renal, and haematological manifestations (8, 9). Extraglandular 
manifestations occur in approximately 50 % of children with jSS (4). Criteria for jSS are not 
available in current literature (10-12) and neither the American-European Consensus Group 
(AECG) criteria (2) nor the American College of Rheumatology/European League Against 
Rheumatism (ACR-EULAR) criteria (13) have been validated in a juvenile population. In 
addition, the AECG criteria may not be applicable due to diverse clinical manifestations in 
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Interest regarding ultrasonography examination of the major salivary glands (SGUS) (14) as a 
diagnostic tool for pSS is increasing (15-19). Salivary gland US may serve as a supplement, or 
even alternative, to minor salivary gland biopsy (11, 17). Development of a non-invasive, 
diagnostic method for evaluation of the salivary gland component, to aid the diagnosis of jSS 
is especially important in the younger population, both with regard to the in some patients 
late onset of sicca-symptoms, and current lack of diagnostic criteria. Previous studies 
indicate that SGUS may be of value in establishing a jSS diagnosis (7, 20, 21). However, 
current reports include small numbers of patients and SGUS application remains to be 
evaluated in a larger cohort. Further studies on jSS are needed and to our knowledge our 
study is to date the largest cohort for this patient group. The aim of this study was to 
characterize symptoms and clinical findings in patients with jSS and to investigate SGUS as a 
diagnostic tool for jSS. 
 
MATERIALS AND METHODS 
Patients 
The study design is a cross-sectional multicentre study. Patients were recruited from 
Haukeland University Hospital in Bergen, Norway, Oslo University Hospital, Norway, Hospital 
General Universitario Gregorio Marañón in Madrid, Spain, Hospital Universitário Cassiano 
Antônio Moraes of Federal University of Espírito Santo in Vitória Brazil, Hospital 
Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro in Brazil and 
Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP) in 
Brazil, University Medical Center Groningen, the Netherlands, and Department of Pediatrics, 
University of Florida, Gainesville, Florida. Patients had previously received the diagnosis jSS, 
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the time of inclusion, all patients were younger than 25 years. Identification of patients at 
each clinic was performed by the local specialist in rheumatology or paediatric medicine.  
Clinical examination, sialometry and SGUS were performed in all patients. Upon inclusion, 
patients were asked for EGM, and medical history was collected from medical charts, 
including information regarding autoantibodies, biopsy results and current/previous 
treatment.  
Patients recruited in Norway (n=11), Spain (n=5) and Brazil (n=40) were examined and 
included by the primary investigators, SDH/MVJ, with the local specialist. Patients recruited 
from the Netherlands (n=8) and USA (n=3) were examined in collaboration with local 
experts and included retrospectively.  
Being a cross-sectional study, not all clinical examinations and tests had been performed or 
were available in all patients.  
 
Subjective symptoms a d EULAR Sjögre ’s S dro e Patie t Reported I de  ESSPRI  
EULAR Sjögre ’s S dro e Patie t Reported I de  ESSPRI  (22) was determined upon 
inclusion. Children were aided by an accompanying parent/guardian, when necessary.  
 
EULAR Sjögre ’s s dro e disease activit  i de  (ESSDAI) 
EULAR Sjögre ’s syndrome disease activity index (ESSDAI) (23) was registered upon 
inclusion. The haematological and biological domains were determined from the most 
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Tear secretion 
Tear secretion was evaluated by the Schirmers-I test. Wetting of the strip was recorded in 
mm, with levels of 5 mm or less wetting of the paper strip considered as pathologically 
reduced tear secretion. 
 
Sialometry 
Salivary gland functional capacity was evaluated by unstimulated sialometry measured in 
ml/15 minutes, with the patients fasting 90 minutes prior to examination. The volume of 
saliva was determined by weighing, with 1 gram corresponding to 1 ml. Saliva secretion 
levels  1.5 l/15 i utes ere o sidered pathologically reduced. 
 
Salivary gland ultrasonography 
The SGUS examination of the parotid and submandibular glands was performed using linear 
high-frequency transducers (6-15 MHz) and a simplified scoring system. Glandular 
homogeneity and presence of hypoechogenic areas were evaluated and graded (0-3). 
Grades 0-1 were considered to correspond to normal/non-specific changes and grades 2-3 
to correspond to pathological changes (Figure 1). The SGUS was performed and scored bed-




This study was performed in accord with the Regional Medical and Health Research Ethics 
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participating centers/countries (Norway: 145/96-44.96, 242.06 2009/686; Brazil: 
4478701544787015447870151.433.660/201644787015.6.2001.0068.) Informed consent 
was obtained from all participants and from parents of patients < 16 years old, according to 
the Declaration of Helsinki.  Parents/legal guardians of under-aged patients were present at 
inclusion (clinical examination and SGUS imaging). In Spain, the Netherlands and USA, the 
non-invasive study design and number of patients included were in accordance with 
regional ethical guidelines and did not need a specific project approval.  
 
Statistical analysis 
The Stude t’s t-test ith Wel h’s orre tio  as used to stud  differe es et ee  groups 
and Pearson correlation for the relationship between two variables. Correlations within 
ranges 0.0-0.2 were considered as poor, 0.2-0.4 as fair, 0.4-0.6 as moderate, 0.6-0.8 as good 
and 0.8-1.0 as excellent. 
For categorical data Chi-square analysis was employed. To adjust for type 1 error due to 
multiple comparisons Benjamin-Hochberg adjustment was applied. All analyses were 




Our cohort consists of 67 patients. The female:male ratio was 58:9. Mean age at first 
symptom was 10.2 years (range 1-17), 12.1 years (range 4-18) at diagnosis and 16.3 years 
(range 6-25 years) at inclusion (Table 1).  
Out of the 67 patients, 35 (52%) and 39 (58%) patients fulfilled the AECG (2) and ACR-EULAR 
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fulfilled both criteria and 42 (63%) fulfilled either the AECG or the ACR/EULAR criteria. One 
patient had mixed connective tissue disease (MCTD) and seven patients were diagnosed 
with systemic lupus erythematosus (SLE) (Table 1). 
In the patients with MCTD/SLE (n=8), 7/8 patients presented with autoantibodies, and 
fulfilled the AECG and the ACR-EULAR classification criteria. In this subgroup, 6/8 had ocular 
symptoms and 5/8 had ocular signs. All patients had experienced major salivary gland 
swelling and 6/8 had salivary gland involvement by sialometry (n=2), scintigraphy (n=2), 
sialometry and scintigraphy (n=1), or sialometry, scintigraphy and sialography (n=1). Five 
had available minor salivary gland biopsy; the three patients lacking biopsy did have 
objective evidence of salivary gland involvement, either by a positive scintigraphy (n=1), 
sialometry and scintigraphy (n=1), or sialometry, scintigraphy and sialography (n=1). All five 
biopsies were positive, i.e with a focus score of  1, corresponding to one or more chronic 
inflammatory cell foci consisting of 50 or more cells per 4mm2 of otherwise normal-
appearing minor salivary gland tissue. In comparison, for the remaining patients (n=59) not 
diagnosed with an additional connective tissue disease, information on minor salivary gland 
biopsy was available from 29 patients, with a positive biopsy in 23 cases. Among these, the 
accurate focus score was available from 16 patients; 15/16 biopsies were positive (focus 
s ore  1 . Interestingly, all MCTD/SLE patients had extraglandular manifestations and three 
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Subjective symptoms 
Subjective ocular and oral dryness symptoms were noted in 42/67 (63%) and 53/66 (80%) 
patients, respectively (Table 2). Only 8/66 (12%) reported no dryness symptoms. Ocular 
signs were noted in 26/40 (65%) patients with ocular symptoms (p=0.004).  
Subjective oral symptoms were not associated with a positive minor salivary gland biopsy or 
objective salivary gland involvement (sialometry, sialography or scintigraphy). 
Sialoscintigraphy and/or sialography had been performed in thirty-one patients (Table 2), 
though interestingly only in the Brazilian part of the cohort. 
ESSPRI for dryness correlated non-significantly with age at inclusion (p=0.062, n=58). Mean 
ESSPRI for patients (n=25) not fulfilling classification criteria was 2.7 compared to 4.0 for 
patients (n=40) fulfilling either AECG and/or ACR-EULAR classification criteria for pSS 
(p=0.04).  
 
Major salivary gland imaging (SGUS) and glandular characteristics  
Pathological SGUS findings (Figure 1, C-D) were observed in 41/67 patients. Mode SGUS 
score was 2 for all glands. The sum of the SGUS score (0-12) correlated with the ACR-EULAR 
points (r=0.321, p=0.016, n=56) (Figure 2). Interestingly, SGUS+ findings were observed in 
26/27 of the European and North American patients as compared to 15/40 of the Brazilian 
patients (p=0.001). 
Subjective sicca symptoms were not associated with pathological SGUS findings; ocular 
symptoms were noted only in 19/41 (46%) SGUS+ patients compared to 23/26 (88%) SGUS- 
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16/24 (67%) SGUS- patients (p=0.050). Oral symptoms were noted in 30/40 (75%) patients 
with SGUS+ compared to 18/26 (69%) with SGUS- (p=0.607).  
Salivary gland involvement (sialometry, sialoscintigraphy and sialography) was noted in 
41/61 (67 %) patients; 20/35 (57 %) SGUS+ and 21/26 (81 % %) with SGUS- (p=0.052) (Table 
2). When considering the individual items for salivary gland involvement, unstimulated 
whole saliva levels (ml/15 min) correlated inversely with the sum of the SGUS score (0-12) 
for all four glands (r=-0.324, p=0.015, n=56) (Figure 2), and with the SGUS score (0-3) for 
both submandibular glands (r=-0.372, p=0.005, n=56) and (r=-0.301, p=0.024, n= 56), right 
and left gland, respectively. A correlation was also observed in the right parotid gland (r=-
0.285, p=0.033, n=56). Mean level of saliva was 5.6 ml/15 minutes in SGUS- patients 
compared to 3.3 ml/15 minutes in the SGUS+ patients (p=0.049), but when comparing saliva 
cut-off le els  1.5 l/15 i utes  SGUS+ patients were below threshold in 11/34 (32%) 
cases, compared to 9/26 (35%) SGUS- patients (p=0.854). Scintigraphy findings coincided 
with both normal and pathological SGUS findings (p=0.350) (Table 2).  
Information regarding labial minor labial salivary gland biopsy was available in 34 patients. 
Among these, 28/34 (82%) patie ts had a fo us s ore  1, 21/26 (81%) SGUS+ compared to 
7/8 (88%) SGUS- (p=0.662) (Table 2). For 20 patients the precise focus score was available, 
ranging from 0 to 8 with a mean of 1.7. Mean focus score was 1.9 in the SGUS+ patients 
(n=16) compared to 1.0 in the SGUS- patients (n=4), but the difference was not statistically 
significant (p=0.368), most likely due to low numbers. This probably also influenced the lack 
of correlation between precise focus score and total SGUS score, both when considering the 
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In total, 37/58 (64%) patients had experienced salivary gland enlargements/parotitis (Table 
2) and although not significant, a trend was noted with regard to pathological SGUS findings; 
25/34 (74 %) patients with SGUS+ had experienced salivary gland swelling, compared to 
12/24 (50 %) SGUS- patients (p=0.066).  
 
Autoantibodies  
The majority of patients, 50/67 (75%), presented with anti-Ro/SSA and/or anti-La/SSB. In 
the group with SGUS+ findings, 36/41 (88%) patients were anti-Ro/SSA positive, whereas in 
the SGUS- group only 14/26 (54%) patients were anti-Ro/SSA positive (p=0.002). Similarly, 
SGUS+ was associated with anti-La/SSB; 23/41 (56%) of the SGUS+ patients were anti-
La/SSB+, whereas only 4/26 (15%) of the SGUS- patients were anti-La/SSB+ (p=0.001), and 
24/39 (62%) of the SGUS+ patients were positive for RF, whereas only 5/25 (20%) of the 
SGUS- patients were RF+ (p=0.001) (Table 2).  
Interestingly, 11/36 (31%) SGUS+ patients with positive anti-Ro/SSA did not fulfil the current 
classification criteria for pSS (2, 13). Out of these eleven patients, all did not fulfil or were 
lacking one or several items; ocular symptoms (n=11, 3 positive), oral symptoms (n=10, 7 
positive), ocular signs (n=11, all negative), minor salivary gland biopsy (n=3, all negative), 
salivary gland involvement (n=6, 2 positive), sialoscintigraphy (n=1 positive), sialometry 
(n=6, all negative), OSS (n=6, one positive). Six patients had experienced salivary gland 
swelling; two of these had also experienced lacrimal gland swelling. 
Taking a closer look at patients not fulfilling classification criteria for pSS (n=25), 11/25 (44 
%) presented with anti-Ro/SSA and SGUS+, whereas the remaining (n=14) were either 
SGUS+ but lacked anti-Ro/SSA (n=4) or were anti-Ro/SSA- and had a normal-appearing SGUS 
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/SSA- patients, all had pathological findings by sialoscintigraphy, 9/10 (90%) were ANA+, 
3/10 (30%) had pathological levels of UWS, whereof one also had a positive sialography. 
One of the SGUS-/anti-Ro/SSA- patients was diagnosed with SLE.  
 
Extraglandular manifestations 
Various EGM at some time-point had been noted in 56/62 (90 %) patients (Table 3). Mean 
ESSPRI total was 4.0 for patients (n=40) fulfilling classification criteria for pSS (2, 13) 
compared to 2.7 for the remaining patients (n=25) (p=0.040). ESSPRI pain was also increased 
in patients fulfilling the AECG and/or ACR-EULAR classification criteria for pSS, with mean 
levels 3.5 compared to 1.9 (p=0.05).  
Mean ESSDAI was non-significantly higher in the SGUS+ compared to for the SGUS- patients 
(p=0.138) (Table 3).  
 
Treatment 
Symptomatic treatment was observed in 29/59 (49%) patients (Table 4). Symptomatic 
treatment was registered in 16/34 (47 %) SGUS+ patients compared to 17/25 (68 %) with 
SGUS- (p=0.109). Only 5/59 (8%) patients had received salivary substitutes; four of these 
patients had SGUS+. Three patients had received Pilocarpine, none had received Cevimeline. 
A higher number of patients, 30/59 (51%), had received or were using lacrimal substitutes, 
where of the majority, 18/30(72%) had normal SGUS (p=0.005) (Table 4). Mean ESSPRI for 
dryness was 4.1 for patients who had received symptomatic treatment compared to 2.4 for 
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Current or previous use of NSAIDs was noted in 16/34 (47 %) SGUS+ patients compared to 
9/25 (36 %) SGUS- patients (p=0.396). Out of 59 patients, 54 were currently (n=40) or 
previously (n=14) treated with hydroxychloroquine. Interestingly, 29/34 (85 %) SGUS+ 
patients had hydroxychloroquine experience, whereas 25/25 (100 %) SGUS- patients had 
used or were using hydroxychloroquine (p=0.045). When instead comparing never users 
(n=5) and previous users (n=14) to current users (n=40), 18/34 (53%) SGUS+ and 22/25 (88 
%) SGUS- patients were on current treatment (p=0.004) (Table 4). 
Interestingly, systemic treatment was noted in 56/59 (95 %) patients, and was associated 
with EGM in 52/53 patients (p=0.001). In ten patients systemic treatment was ceased, and 
42/53 patients with EGM were currently receiving systemic treatment (p=0.481). In 40/46 
(87 %) the systemic treatment was current hydroxychloroquine (p=0.001).   
 
DISCUSSION 
To date, this is the largest study investigating clinical characteristics of patients with jSS in 
combination with SGUS. The female:male ratio was approximately 6.5:1, i.e. slightly altered 
with more male patients as compared to 9:1 for adults with pSS (24-27). The mean time 
from symptom debut to diagnosis was 1.8 years, naturally shorter than in adult pSS patients, 
where the time from debut of symptoms to diagnosis spans up to 11-14 years (26).  
Nearly 2/3 of the patients fulfilled the current classifications criteria for pSS, and there were 
no significant differences in the application of the 2002 AECG (2) and the ACR-EULAR criteria 
(13). Due to different practices between regions and the fact that not all examinations in the 
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that patients not fulfilling the classification criteria in this study would still not fulfil criteria, 
were all necessary examinations performed.  
Major salivary gland ultrasonography findings were associated with anti-Ro/SSA and anti-
La/SSB, similar to previous findings in adult pSS (28). Out of the 36 SGUS+ patients with 
positive anti-Ro/SSA, 11 patients did not fulfil the AECG or ACR-EULAR classification criteria, 
due to lack of objective salivary or lacrimal gland involvement such as reduced salivary 
and/or lacrimal secretion. Out of these 11 patients, 6/8 had registered salivary gland 
enlargement. 
When considering the patients not fulfilling classification criteria for pSS (n=25), 11 (44 %) 
were anti-Ro/SSA+ and SGUS+, 4 (16 %) were SGUS+ and anti-Ro/SSA-, and 10 (40 %) were 
anti-Ro/SSA- and SGUS-. Among the anti-Ro/SSA- patients 11/14 (78.6 %) were ANA+. In 
addition, all the anti-Ro/SSA- and SGUS- patients had previously documented salivary gland 
involvement by sialoscintigraphy. Our findings thus support the notion that the existing 
criteria for pSS are not optimal for clinical evaluation and research of jSS (10, 12, 29). Of 
note, among the individuals fulfilling either the AECG or the ACR-EULAR classification 
criteria, 1/42 SGUS+ patients was ANA+ but anti-SSA/Ro-. Concerning the individuals 
fulfilling both AECG and ACR-EULAR criteria, all 19/19 SGUS+ patients were anti-Ro/SSA+ 
compared to 11/13 of the SGUS- patients (p=0.077). Interestingly, other relevant 
autoantibodies such as anti-La/SSB and RF were also associated with SGUS findings, further 
supporting the link between autoantibodies and salivary gland involvement in jSS.  
In this cohort of patients with jSS, pathological SGUS changes (61 %) were slightly more 
common compared to adults (30) and non-significantly associated with salivary gland 
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higher SGUS score was associated with lower levels of unstimulated whole saliva (28), non-
significantly associated with oral dryness symptoms. Treatment of oral dryness symptoms 
was rare, but linked to SGUS+ in 4/5 cases. Ocular sicca symptoms and symptomatic 
treatment of dry eye was more common in SGUS- patients. Interestingly, ESSPRI dryness 
showed a trend to increase with age at inclusion (p=0.062). One might speculate whether 
this is due to actual later onset of sicca symptoms, or that oral dryness is not perceived as a 
problem by the younger patients.  
Although mean focus score was higher in SGUS+ compared to SGUS-, and imply that focus 
score can mirror the degree of damage visualized by SGUS, comparison of findings in the 
major and the minor glands were limited due to lack of data on minor salivary gland focus 
score. 
Similar to earlier reports in both pSS and jSS, the patients in this cohort display a high 
degree of EGM (30, 31). Both mean ESSPRI and mean ESSPRI pain was higher in the patients 
fulfilling AECG and ACR-EULAR classification criteria, and mean ESSDAI was non-significantly 
higher in the SGUS+ compared to the SGUS- patients.  
Eight patients with EGM differed from their jSS peers, in several aspects. All eight had at 
some point been diagnosed with SLE or MCTD and three had renal affection, an EGM with a 
varied prevalence of 2 to 67 percent in pSS (32-34). Kidney involvement was not observed in 
any other patients in the cohort. Although 7/8 patients did fulfill the classification criteria 
for pSS, a possible misdiagnosis cannot be ruled out as differentiation between various 
connective tissue diseases can be difficult. Nonetheless, 3/8 SLE/MCTD patients presented 
with SS-like SGUS changes such as hypoechogenic areas and inhomogeneity (27), consistent 
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In line with EGM, previous or current systemic treatment was also quite frequent, especially 
in patients with EGM. For the majority of patients, the current systemic treatment was 
hydroxychloroquine. Interestingly, only 18/40 of patients with current hydroxychloroquine 
treatment displayed SGUS+ changes, whereas 16/19 without current treatment showed 
changes. These results should however be interpreted with care, as there is both a higher 
proportion of patients with EGM (39/40 vs 14/19, p=0.005), current systemic treatment 
(37/40 vs 9/19, p=0.001) and a lower degree of SGUS+ in a subgroup of the cohort 
consisting of patients included in Brazil compared to Europe/USA (15/40 vs 26/27, p=0.000) 
and a possible confounding factor cannot be ruled out. Patients in this subgroup were also 
older when included, and the mean time from diagnosis to inclusion was higher.  
 Studying the current group of patients revealed variation in subjective symptoms, clinical 
findings, application of diagnostic tests/methods, and treatment regimes. More invasive 
diagnostic methods (such as sialoscintigraphy and sialography, compared to sialometry) and 
systemic treatment (Azathioprine and high dose corticosteroids/prednisone) was observed 
in the subgroup of the cohort consisting of patients included in Brazil, possibly due to a 
higher incidence of EGM. 
The data was a combination of newly acquired and retrospective data. In consequence, 
shortcomings include lack of new blood tests and incomplete clinical data, limiting the 
application of AECG and ACR/EULAR classification criteria. Different ultrasonography 
machines and probes were used for the SGUS examination, possibly affecting the results 
obtained. To move forward, a prospective study with more rigorous design, a more 
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characterize this rare condition and establish adequate criteria for diagnosis and 
classification. 
In conclusion, findings in the jSS patients studied indicate an association between SGUS 
findings, hyposalivation and autoantibodies. In many patients, SGUS was also associated 
with salivary gland swelling, a previously known and common clinical finding in jSS. SGUS is 
an interesting diagnostic tool for identifying patients with jSS.  
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Figure 1: Representative major salivary gland ultrasonography (SGUS) images of submandibular 
glands illustrating grade 0 (A), grade 1 (B), grade 2 (C) and grade 3 (D), with grades 0-1 (A-B) 
corresponding to normal-appearing morphology, and grades 2-3 corresponding to pathological 
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Figure 2: Total SGUS score (0-12) for all four glands correlated with the total sum of the ACR/EULAR 
classification criteria points (0-9) (p=0.016) (A), and unstimulated whole saliva flow (0-21.36 ml/15 
min) (p=0.015) (C). The correlations were not significant after Benjamin-Hochberg adjustment.  
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